

THE APLASTIC ANAEMIA TRUST

England & Wales · Charity number 1107539

Details

Status Registered

Legal form Charitable company

Company number [05174065](#)

Registered 2005-01-10

Register [View on the Charity Commission register](#)

Contact

Address C/O KM Chartered Accountants
Burnley Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

Phone 07813857966

Email support@theaat.org.uk

Website www.theaat.org.uk

Activities

Objects: TO RELIEVE THE SICKNESS OF THOSE PEOPLE SUFFERING FROM BONE MARROW DISEASE AND IMMUNE DEFECTS.

Activities: The AAT is a charity dedicated to supporting sufferers of aplastic anaemia and allied disorders. Few people know about this disease despite the fact that it is as common as some types of leukaemia and just as devastating. The AAT is also dedicated to the provision of support for patients and their families in the form of our AA Support Group

Classification

- **How:** Makes Grants To Organisations, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups

Geography

- **Area of benefit:** NATIONAL
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£647,210	£593,793	£471,980	11
2024-03-31	£478,770	£500,325	-	-
2023-03-31	£474,300	£481,405	-	-
2022-03-31	£233,189	£240,335	-	-
2021-03-31	£222,766	£151,461	-	-

Trustees

Name	Role	Appointed
Amanda Conquy	Chair	2020-04-29
Callum Tempest		2022-08-31
JANE COZENS		2018-04-12
Jenny Williamson		2023-02-16
Kavita Agarwal		2025-03-31
Sarah Gilbert		2022-08-31
Steve Oliver		2022-11-30

THE APLASTIC ANAEMIA TRUST

England & Wales - Charity number 1107539

Accounts

Company registration number: 05174065

Charity registration number: 1107539

Charity number (Scotland): SC049810



**the
aplastic
anaemia
trust**

The Aplastic Anaemia Trust

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2025

KM
Chartered Accountants
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

The Aplastic Anaemia Trust

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 14
Statement of Trustees' Responsibilities	15
Independent Auditors' Report	16 to 19
Statement of Financial Activities	20
Balance Sheet	21
Statement of Cash Flows	22
Notes to the Financial Statements	23 to 30

The Aplastic Anaemia Trust

Reference and Administrative Details

Trustees	A Conquy C Tempest J L Cozens J Williamson K Agarwal S Gilbert S Oliver
Principal Office	1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
Company Registration Number	05174065
Charity Registration Number	1107539
Charity Registration Number Scotland	SC049810
Bankers	CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 5JQ
Auditor	KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG

The Aplastic Anaemia Trust

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 31 March 2025.

Trustees

A Conquy

C Tempest

J Beart (resigned 31 May 2025)

J L Cozens

J Williamson

K Agarwal (appointed 31 March 2025)

S Gilbert

S Oliver

T Stephenson (resigned 30 April 2025)

Research and Clinical Advisory Panel

Professor Josu de la Fuente

Dr Morag Griffin

Dr Austin Kulasekararaj

Dr David Irvine

Professor Ghulam Mufti (Chair)

Dr Bethany Mitchell

Dr Sujith Samarasinghe

Professor John Snowden

Professor Rod Skinner (Vice Chair)

Dr Sanjay Tewari

Professor Alan Warren

Dr Keith Wilson

Callum Tempest (Patient Advocate & Trustee)

INTRODUCTION

The Aplastic Anaemia Trust (AAT) has continued to be the leading organisation supporting patients with aplastic anaemia and their families, as well as people with other rare bone marrow conditions. This past year has seen us expand our support offer through both in person and digital offerings, invest in groundbreaking research projects, develop new relationships with leading healthcare professionals and crucially grow our community.

Despite the ongoing cost-of-living crisis and rising prices, income generation has remained strong due to our community, partners and funders. We are deeply grateful for the efforts of our community in continuing to fundraise and support us during these difficult times.

The AAT has worked with external partners to carry out an equality, diversity and inclusion audit of the organisation, develop an ED&I strategy and begin the process of implementing recommendations and embedding practices. There has also been a greater focus on monitoring and evaluation to ensure the support we offer is meeting the needs of our community.

The Aplastic Anaemia Trust

Trustees' Report

The National Health Service has remained under strain in all four nations of the UK and this has continued to impact our patient community when accessing treatment or related services such as mental health support. The AAT has continued to provide one-to-one and group support for our community, produce industry leading patient information free of charge, offer psychological support and professional benefits advice. These services could not be possible without the support of our strategic partners and funders.

We continued to put patients' voices at the heart of everything we do and our commitment to delivering change for them has never been stronger. We launched our campaign to get aplastic anaemia listed on the NHS website. A search for aplastic anaemia on the NHS England website would only bring up results relating to anaemia (Iron deficiency) which causes frustration among patients looking for support and confusion among their families and some professionals. Since the launch of the campaign we have already made significant progress, the issue has been raised in the House of Commons and we have had success in Scotland as the NHS Inform website has been updated to include aplastic anaemia.

The Better Together For Healthy Marrow Partnership continues to be a huge benefit for the AAT and the rare bone marrow disease community as the project approaches the end of its current funding in August 2025. The six small but mighty organisations in this partnership are:

- The Aplastic Anaemia Trust
- CAN (Congenital Anaemia Network)
- DC Action
- Fanconi Hope
- PNH Support
- SDS UK

We work together to deliver improved support for our communities - people affected by a range of related rare bone marrow failures that are not caused by cancer. Together we have continued to provide excellent psychological and emotional support in the form of courses, as well as 1-1 provision. We have delivered a range of training courses for our members and the rare bone marrow failure community. The partnership also delivered our most successful 'Super Rare' community fundraising campaign to date.

As a small charity who strive always to punch above our weight, strong partnerships are key to our organisational strategy. This approach is enabling us to deliver both support and research more effectively and at a higher quality than we could achieve alone.

This past year has brought us towards the end of our current strategy cycle and created an opportunity for us to both reflect on the progress the Aplastic Anaemia Trust has had and where we wish to go in the future.

OBJECTIVES AND ACTIVITIES

What is Aplastic Anaemia?

Aplastic anaemia is a rare and life-threatening form of bone marrow failure. It can affect people of any age, but it is most common in children and older people.

The majority of cases are acquired, but many of our community are also diagnosed with inherited types of aplastic anaemia. The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every person diagnosed with aplastic anaemia and their loved ones, to help relieve the immense disease burden. We estimate 150 to 250 people per year are diagnosed with AA - there is no registry collecting this information at the moment so it is impossible to give an accurate number. However we know from our clinical networks that this figure is on the rise in adults and children.

The Aplastic Anaemia Trust

Trustees' Report

Our Mission, Vision and Objectives

The objectives of the charity as defined in its Articles of Association are to relieve the sickness of those people suffering from bone marrow disease .

Vision:

Everyone affected by aplastic anaemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.

Mission:

We deliver our vision through two key missions:

- Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
- Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.

Our strategic objectives

A. Ensure everyone affected by aplastic anaemia has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.

B. Improve the knowledge and understanding of aplastic anaemia through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.

C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes.

D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.

Our fundraising acts as an enabler in our strategy, ensuring we have the resources to deliver these objectives.

CHALLENGES OF 24/25

Growth and Transition

After nearly five years with the Aplastic Anaemia Trust, Stevie Tyler announced she was leaving the charity. During her time as Chief Executive, the charity grew from one staff member to eleven team members (8.1 FTE), critical clinical and community reference groups were instituted, the Better Together for Healthy Bone Marrow charity alliance began and countless relationships with key stakeholders, strategic partners and funders were established. As with any change of this nature there is substantial risk that these relationships may not be maintained and the hard fought for growth slips back. However thanks to the rigorous and thorough recruitment put in place by the Trustee Board with the support of an external recruitment agency they appointed an experienced charity leader who was able to maintain and grow these strategic partnerships, quickly establish meaningful relationships with stakeholders and provide reassurance to the AAT staff team through attending our staff conference and meeting with team members before taking up the post. The new Chief Executive, Joe Kirwin, joins us having most recently been the Chief Executive of a national cancer charity.

Our staff team also continued to grow which is both a positive and a challenge as we meet the hurdles of upscaling projects. This past year we were able to add additional resource to our fundraising team allowing us to better support our community fundraising ambitions and our volunteers. Fitting in with our research aims included in the current strategy, the AAT also invested in appointing a Clinical Research Project Manager to allow us to give research the dedicated focus it needs to grow and deliver results for our community.

The Aplastic Anaemia Trust

Trustees' Report

Ongoing pressure in the NHS and the Ten-Year Plan

Aplastic anaemia is an ultra-rare condition, and as the UK health system faced another turbulent year, with services overstretched, our work to support patients and their families has been more important than ever. Integrated Care Boards had significant budget reductions, all but two NHS foundation trusts reported a deficit, it was announced that NHS England would be abolished and the ongoing workforce shortage continues to impact patients. While there has been a small improvement in length of time that patients have been waiting for emergency, routine and cancer treatments which frequently applies to our community too, this has not been significantly large for our patient community to have experienced the impact.

Whilst we continue to support the UK Government Rare Disease Framework and the ambitions set out within the plan there does not yet appear to be any result that has tangibly improved the care, treatment or diagnosis pathway of those with aplastic anaemia or other rare bone marrow failure conditions. The current Rare Disease Framework plan is due to come to an end in 2026 and going forward the Aplastic Anaemia Trust will work to influence the Governments in all four nations to deliver on the promises set out within the plan.

In October 2024 the UK government announced development of a new 10-year Health Plan for England. The plan aims to ensure the NHS is fit for the future by focusing on three 'shifts':

1. Moving care from hospitals to communities.
2. Making better use of technology
3. Focusing on preventing sickness, not just treating it

At time of writing the new NHS 10 Year plan is still in development and it is still unclear what the potential impact on the aplastic anaemia and other rare bone marrow failure condition communities will be. Regardless of the final version of the 10 Year Plan, the AAT will continue to champion patients and ensure that decision-makers hear their voices.

What did people affected by aplastic anaemia need in 2024?

We have seen a significant increase in the number of patients, their families and healthcare professionals accessing our patient information. This growth in demand has partly come around due to news in the previous financial year that our fellow charity, Leukaemia Care, informed us that they would no longer produce patient information about aplastic anaemia, and would instead signpost hospitals and healthcare professionals to order this from us. We have also seen growth in the number of people contacting us for support, whether by phone, email, or interacting via our private Facebook Support Group, which has more than 2,600 members.

We have also recorded a significant increase in the number of people accessing trusted information and support via our website. Our 'What is aplastic anaemia?' webpage is one of the most frequently accessed pages on our website, and it was viewed on 3154 occasions, by 2225 users based in the UK in 2024-25. In comparison, the same page was accessed on 2606 occasions by 1655 UK-based users in 2023-24, representing a 34% increase in the number of users visiting the page. We believe that this is representative of an increase in demand for people accessing the resources on our website as a whole. In 2024-25, we provided direct support to 320 individuals, compared to 312 individuals in 2023-24.

The Aplastic Anaemia Trust

Trustees' Report

Individuals receiving direct support from Support & Outreach in 2024-25

Country	Number of individuals	Number of interactions
England	278	1,495
Scotland	25	74
Wales	8	11
Northern Ireland	9	70
UK (no nation recorded)	179	700
Other countries (including ROI)	68	154

We know with certainty that we provided direct support to **320 individuals** based in England, Scotland, Wales and Northern Ireland and recorded **1650** interactions with them. We also have another **179 individuals** for whom we do not know for certain where they are based within the UK, and logged **700** interactions with them.

In 2024-25, we focussed on developing relationships with clinicians across the UK to raise awareness of the support that we can offer to their patients. In total, we contacted 127 clinicians and allied health professionals based in the UK.

Clinicians supported/contacted in the UK

Country	Number of clinicians contacted
England	90
Scotland	27
Wales	8
Northern Ireland	2

Our efforts to raise awareness of The AAT resulted in clinicians ordering 28 different publications, information booklets and leaflets to provide accurate and reliable information to their patients - in total, **907** individual copies of our resources were sent out to clinicians in 2024-25.

Regardless of the stage in their treatment journey at which a person affected by aplastic anaemia reaches out to us, we are often in contact with our community members on numerous occasions throughout their journey - indeed, it is very unusual for a person to only reach out to us for support on one occasion. In 2024-25, we recorded a total of 1650 support 'interactions' with people based in England, Scotland Wales and Northern Ireland, and a further 700 with people based in the United Kingdom where their precise location is not known, whether that be answering a question via email or phone or signposting them to a specialist to support them with their financial or emotional wellbeing. This resulted in a total of **2350** interactions being recorded with our community members based in the UK.

The Aplastic Anaemia Trust

Trustees' Report

A diagnosis of aplastic anaemia can be incredibly debilitating and impacts every aspect of daily life. In these challenging times, our patient community continues to experience financial challenges, whether related to the ongoing cost of living crisis, or difficulties in accessing, or navigating the welfare benefits system. In 2024/2025 we supported 26 community members with benefit consultants, of whom twenty were supported by benefits advisors at Maggie's Centres across the UK through our partnership with them, and the remaining six received support from the Benefits Advisor provision made available through the Better Together for Healthy Marrow Partnership where Maggie's were unable to help, such as where enquiries concerned benefits for children and young people. In comparison, 21 requests for benefits consultations were made in 2023-24, and 23 requests made in 2022-23. Regardless, we frequently hear from our community about the financial issues and pressures that they face, often exacerbated by issues in applying for benefits such as PIP, where claims are frequently rejected, with our community members having to go through the mandatory consideration and tribunal processes in order to access the benefits that they are entitled to. In turn, this creates an additional practical and psychological burden for those affected by aplastic anaemia, further exacerbating an already difficult situation.

ACHIEVEMENTS AND PERFORMANCE HIGHLIGHTS

How The AAT delivered public benefit in 2024/2025

The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.

In line with the governing document, the Memorandum and Articles of Association, our performance highlights for the last year in relation to the Charity's aims are set out below.

Delivering support

Our small and agile Support and Outreach team are swift to adapt to the evolving needs of aplastic anaemia patients in a rapidly changing world. Investment in the project management of this team has seen these abilities strengthened, as the online services we developed during lockdown are iterated and expanded into in-person support.

This year our support team and small group of dedicated volunteers:

- Delivered informative webinars. These webinars connected people affected by aplastic anaemia with global experts speaking about specific aspects of living with the condition, or they were delivered by a psychologist with the intention of offering emotional wellbeing support to those living with the conditions or those supporting people who are living with the conditions.
- Continued to provide our support packs for children (Bravery Boxes) in hospitals and their siblings left at home, in collaboration with our Youth Board. These include a handmade blanket, a tablet to enable them to access our online resources and a bespoke activity book designed by our Youth Board to support a child's mental wellbeing.
- Grew our bespoke service to provide our expert support to meet the increasing demand and reach even more families, including parents, children, siblings, grandparents and wider family networks.
- Expanded our Winter Wellness programme offering our community various support options to help them through the specific challenges of the winter season including making seasonal befriending calls to more isolated members of our community.
- Emotional resilience training was provided for our staff, volunteers and community.
- Launched our first Moving Forward course at the beginning of this financial year. Importantly, this course was co-created by the psychology team with our community reference group.

The Aplastic Anaemia Trust

Trustees' Report

- Continued to deliver the popular “Mindfulness for Stress” Course and “Managing Stress” Course, designed and delivered by Maggie's psychologists to deliver expert mental health and resilience support to small groups.
- In collaboration with our community reference group (our volunteer patient feedback group) and Maggie's psychologists, co-designed and launched a new course entitled 'Moving Forward: Living the life that matters to you' designed specifically for those people moving on from active treatment.
- Continued to facilitate and moderate daily discussion in our active Patient Support Facebook Group which has over 2,600 members.
- Held regular community support coffee mornings in Leeds, Glasgow and Edinburgh and launched new community support coffee mornings in Birmingham and Lanarkshire.
- Delivered our 6 popular monthly online meet-ups which are focused on specific journey stages, enabling patients and their families to connect with others at the same stage of their journey.
- Delivered our increasingly popular AAT online book club, to help bring our community together in a fun and engaging activity, without the focus being on illness.
- Continued to offer 1-2-1 support via messenger, email, support line calls and WhatsApp as preferred by the individual community member.
- Arranged in-person visits with patients either in hospital or otherwise unable to attend the in-person coffee mornings
- Our Youth Board was created to provide a voice for young people within our organisation, to influence our work directly. Its job is to ensure that The Aplastic Anaemia Trust is supporting young people affected by aplastic anaemia in a way that works for them. It has continued to evolve and grow the activities they run, allowing us to reach more diverse communities. The Youth Board also added new members and continued to offer their voice to ensure that the Support & Outreach team always considers the needs of young people with aplastic anaemia.
- We began the process of developing our innovative ‘Personalised Support Project’ which will allow us to deliver more targeted support to those with multiple conditions.

Building partnerships and Better Together for Healthy Bone Marrow (BT)

Building successful partnerships is at the heart of our organisational strategy, and this year has seen very positive results from this approach. We are approaching the end of Phase 1 of the three-year National Lottery Community Fund project ‘Better Together for Healthy Bone Marrow’.

We have continued to make significant progress in a whole range of areas from organisational resilience building and succession planning to creating spaces for those with rare conditions to come together and delivering innovative test and learn projects. Together we are also providing an ongoing programme of webinars and courses as well as tailored one-to-one support from our Psychology Team.

The current round of Better Together funding is due to come to an end on August 31st, 2025. The team have worked to ensure that there is a detailed delivery plan in place, and we are on track to deliver in full against our commitments with no budget deviations expected.

Other project highlights over the last year included:

- BT has enhanced the organisational resilience of the AAT, and the five partner charities we are working with
- As at the end of March 2025, BT has funded and supported the delivery of an emotional wellbeing framework that has provided:
 - 8 managing Stress & Uncertainty courses, accessed by 108 people
 - 6 Mindfulness courses, accessed by 53 people

The Aplastic Anaemia Trust

Trustees' Report

- 4 Moving Forward courses, accessed by 43 people
- 16 webinars, accessed by more than 250 people
- 1-2-1 support for 47 people
- Collaborative awareness and fundraising campaign, Super Rare, has raised £158,365.52 across the three-year project between the six partners
- Successful community support Test & Learn Pilot Projects, both of which alliance partners wish to continue to run:
 - Cross-community in-person regional support meetings
 - Benefits Advisory Service - information resources and 1-2-1 support
- Continuation funding application seeks to build on existing partnerships, both with partners in the alliance and with external organisations in relation to both support provision and lobbying.

Research highlights

The Aplastic Anaemia Trust enables research into aplastic anaemia and other rare bone marrow failures. We encourage and support research that is truly transformative and can accelerate access to better treatments and cures.

Guided by our Patient Support Group and by our peer-led Research and Clinical Advisory Panel, our research strategy, launched in 2018, focuses on both types of aplastic anaemia - acquired and inherited, in adult and child populations. While the primary focus is on aplastic anaemia, recognising the links with other rare bone marrow failures, we will consider research into dyskeratosis congenita, fanconi anaemia, PNH and others.

Our research priorities

- To improve the understanding of rare bone marrow failures in child and adult populations
- To improve the understanding of the diseases by molecular/ genetic research into the damaged cells and their environment
- To identify risk factors in aplastic anaemia patients that may later lead to MDS (Myelodysplastic Syndrome) or AML (Acute Myeloid Leukaemia)
- To improve treatments, identifying alternative cures, enabling experimental therapies and ultimately eradicate the disease

In Autumn 2024, The Aplastic Anaemia Trust embarked on a project to identify and prioritise the opportunities for improvement in clinical care and research into AA and inherited BMF syndromes. Given the rarity of both AA and constitutional BMF syndromes, diagnosis and administration of appropriate treatments can be delayed, leading to considerable added morbidity and mortality. Furthermore, programmed research funding is grossly deficient in the UK which seriously jeopardises the possibility of identifying novel therapeutic approaches.

Investment in research in the past has been transformative by moving the understanding of the condition forward leading to successful methods of treatment with improved clinical outcomes for patients. To inform future priorities, the Trustees of The AAT, on the advice of The AAT's Research & Clinical Advisory Group (RCAP), led by its chair, Professor Ghulam Mufti, assembled a group of experts to discuss potential future areas of discovery and improvement in research and clinical provision. A conference took place in October 2024 and the resulting report into the priority areas identified will be published in 2025. This report will inform our own future research funding priorities and also, we hope, provide information and context to others working or funding in the field, sparking interest and highlighting opportunities.

The Aplastic Anaemia Trust

Trustees' Report

TIARA clinical trial – Exciting early results

The TIARA Trial at King's College Hospital, which is co-funded between The Aplastic Anaemia Trust and LifeArc is trialling cutting-edge cell therapy to develop a brand new treatment for the condition.

On 7th December 2024, Dr Nazia Matto, the trial's lead GMP (Good Manufacturing Practice) production scientist presented initial findings from the TIARA trial, revealing promising results in a presentation at the American Association on Haematologists (ASH) conference in San Diego.

This stage one trial is investigating the safety and tolerability of expanded autologous regulatory T cells (immune cells, also referred to as Tregs) in treating patients with aplastic anaemia. The early results have confirmed that that Tregs from AA patients are expandable, safe to infuse and may dampen immune system abnormalities associated with the condition.

TIARA trial participants are given two infusions of their own expanded autologous Tregs - a type of cellular therapy - to treat the condition, and will be monitored for two years. Three of the treated patients had been diagnosed with severe AA, two with non-severe, and one with Very Severe AA.

Tregs were successfully expanded from all six patients and all have completed the treatment with both doses. Five patients did so without any safety concerns. One patient developed antibiotic-responsive low-grade fever within 24 hours of the first infusion but received the second dose without any side effects.

A year on from one of the trial participant's treatment, they have gone from being transfusion-dependent to no longer requiring transfusions. Another patient also showed improvements, with red cell transfusion independence lasting 100 days.

The next round of patients are currently undergoing treatment and the AAT is working with researchers to secure additional funding for the second phase of the project and further clinical trials.

Genomic Sequencing to understand Mutation timing and clonal trajectories in aplastic anaemia.

We funded a portion of the costs for a study into Mutation timing and clonal trajectories in aplastic anaemia. This research project brings together researchers from Leeds, Cambridge and the Sangar Institute working in partnership to investigate the genes of people with aplastic anaemia as a first step to find ways to better predict treatment responses and later complications, such as cancer. This project is ongoing and results will be shared with our community in Summer 2025.

A national registry for aplastic anaemia

Following the success of our previous funding for building a national paediatric registry for children with aplastic anaemia in 23/24 we began the process of exploring various avenues to pursue the creation of a national registry, in partnership with existing bone marrow transplant registries. This project has been put on hold because due to the ongoing progress of the UK Government's Rare Disease Framework and the commitment to deliver a Government funded national rare disease registry. We continue to hold the UK Government to account to deliver the commitments made by the end of the current Rare Disease Framework in 2026.

The Aplastic Anaemia Trust

Trustees' Report

FUNDRAISING HIGHLIGHTS

We recognise that the financial year 2024/25 was a particularly tough time for many organisations in the voluntary sector, especially those who do not receive any statutory income from public sector contracts. However, despite these challenging circumstances the Aplastic Anaemia Trust was not only able to meet our income targets but surpass them in the majority of our income streams due to strong relationships we have built with our community and funding partners, as well as being registered with the Fundraising Regulator.

This was the fifth year of running our annual Super Rare campaign, and our third year of running the campaign with the five other small organisations in the Better Together for Healthy Bone Marrow partnership fundraising alongside us with support from our staff team. Collectively all five of the charity partners raised £65,489 with a total of 83 new fundraisers taking part in activity. The AAT alone had 71 New fundraisers sign up and take part. They raised a total of £42,210 against our internal target of £20,000. Over the past three years of partnership we have collectively engaged 157 new fundraisers and raised £158,365 for all charities.

People Powered Fundraising

- We surpassed our individual giving target. We budgeted for £48,453 and the actual income was £102,615. This includes £60,000 from a legacy donation.
- Annual Super Rare campaign engages a record number of fundraisers.
- Our annual Santa Splash in 2024 saw over 100 supporters brave the cold water in Wales, Edinburgh and our new venue Liverpool
- The Peak district Walk 2025 had 75 attendees and raised £3500. This annual event also acts as an in person support session facilitated by members of the Support & Outreach Team being in attendance.
- Our second Big Give Christmas appeal told the story of an adult living with aplastic anaemia and reached our income target within just over 24 hours. We were able to raise a total of £17,880 in the whole of December, and over £16,000 in the Big Give Week alone.
- A community fundraising target of £55,285 was set and actual income was £127,693.
- We were able to grow our regular giving community and exceed our target.
- The Buffy Younger Impact Fund was established. The first of its kind, the Impact Fund will allow our community to have more control over their fundraising and how the money is used.

Trusts, Grants & Foundations

We thank the following Trusts, Foundations and organisations for their funding and support this year:

- David and Rosemary Philips Trust
- Children In Need
- The Hospital Saturday Fund championing our Big Give campaign
- The National Lottery Community Fund
- The Pears Foundation and Contact

The Aplastic Anaemia Trust

Trustees' Report

FINANCIAL REVIEW

How our income and expenditure changed in 2024/2025

Unrestricted income for the year totalled £396,589 (23/24: £196,609) and expenditure amounted to £369,231 (23/24 £224,876) resulting in a net surplus on unrestricted funds for the year of £27,358 (23/24: deficit of £28,267). Restricted income of £250,621 (23/24 £282,161) was received in the year. Expenditure incurred and charged against restricted income funds amounted to £224,562 (23/24: £275,449), leaving balances on restricted funds totalling £142,771 at 31 March 2025.

Managing our income across a range of rare bone marrow failures

As we move into the third year of funding complex partnership projects, it is useful to note with these accounts that the grant income from The National Lottery Community Fund represents budget which is managed by The Aplastic Anaemia Trust to deliver work that is designed to benefit our Better Together partnership of six small organisations (listed above), and the communities of people that all six organisations represent. This project falls within The Aplastic Anaemia Trust's charitable objectives of supporting people suffering from bone marrow disease and by working collaboratively with partnership organisations who are expert in their specific conditions, we can replicate benefits and learning across all our organisations and speak with one voice.

This demonstrates a strategic and forward-thinking approach to having impact in the field of bone marrow failure as per our charitable purpose.

Our reserves position and policy update

The ongoing challenge we face is how to be sure of sustainable funding for these essential support services, while also being able to invest in research.

In response, our reserves policy has been updated for 24/25 to ensure we hold between 6 and 9 months core operating costs in unrestricted reserves (previously 9 months), so that the charity will be able to maintain vital services and re-establish our income, should one source of income drop unexpectedly. Our reasoning, method of calculating required funds, and the purpose for retaining these reserves are outlined in our reserves policy.

The 6-9 months of core operating costs will be recalculated annually. As at March 2025 we calculated that the target range should be £179k - £269k and unrestricted reserves stand at £329k (£60k above target and representing 11 months of core operating costs). We took the decision to phase the spend down over two years, to manage the financial instability we were seeing, and by March 2026 expect to have reduced unrestricted reserves to our target.

Our priority for the next financial year is to continue to seek funding to cover the costs of work delivered by our support team, which will provide confidence that our current level of support is sustainable and enable us to invest future income raised by community fundraising in research partnership projects. This budget does not include investment in new research projects, however we are investing in some expert fundraising resource to run a feasibility study on the research funding landscape, and to establish whether the AAT should be investing in this area of fundraising as an additional budgeted income stream over and above the current financial framework.

The Aplastic Anaemia Trust

Trustees' Report

Pharmaceutical industry income in 24/25

In 2024/25 we continued to develop strong and collaborative relationships with Sobi, Roche, Alexion AstraZeneca Rare Disease, Pfizer and Ono.

We have been pleased to receive funding from the following pharmaceutical companies this year:

Alexion AstraZeneca Rare Disease	Sponsorship of the <i>Future of Aplastic Anaemia Research</i> Conference October 2024	£5,000
	Sponsorship of the Personalised Support Project	£15,000
	Sponsorship of <i>Winter Warmth</i> webinars and sunshine magazines	£15,000
Sobi	Grant funding towards the Personalised Support Project	£15,000
	Sponsorship of the <i>Future of Aplastic Anaemia Research</i> Conference October 2024	£5,000
	Sponsorship of the <i>Better Together for Healthy Bone Marrow</i> Community Conference to take place July 2025	£10,000
	Payment for delivery of an in-person AA presentation	£403
Roche	Sponsorship of the Personalised Support Project	£15,000
	Sponsorship of the <i>Future of Aplastic Anaemia Research</i> Conference October 2024	£5,000
Pfizer	Sponsorship of the <i>Future of Aplastic Anaemia Research</i> Conference October 2024	£5,000
	Payment for reviewing materials	£250
Ono	Payment for in-person AA presentation and materials review	£942

In line with our funding policy, income from pharmaceutical companies is limited to no more than one third of our overall income, ensuring a diverse and balanced funding portfolio.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Evolution of our board

Following the successful embedding of trustees into the organisation through offering training and attendance at staff conferences who had been recruited in previous financial years, some of our longer-serving Trustees felt the confidence to move on from their position, knowing that the Board will have the knowledge, skills and experience to carry out its functions effectively. We wish to extend our thanks to Tracy Stephenson and to Julia Beart for their many and important contributions as trustees. We were very pleased to welcome Kavita Agarwal as the newest member of the Board. She brings lived experience as a parent of a child with aplastic anaemia. Professionally, Kavita has spent much of her career in marketing and business strategy with Diageo and Unilever, working with teams across the globe to develop brands, grow businesses, and navigate change. She has also previously been involved with charities focused on youth employment and the arts, where she has helped with governance and strategic planning.

The Aplastic Anaemia Trust

Trustees' Report

Research and Clinical Advisory Panel and Youth Board

Our Research and Clinical Advisory Panel welcomed Dr David Irvine as a new representative from Scotland. Callum Tempest also joined the Research & Clinical Advisory Panel as a representative of the Trustee Board. The rest of the board remains the same and we thank them for their ongoing service.

There were also changes to our Youth Board. India Wyldmore-Smith and Daisy Hall left the board during this year, having simply reached too great an age (i.e. over 25 years old) to sit on the Youth Board. We were also pleased to welcome new members. The membership currently consists of Ella Bearpark (Co-Chair), Sophie Ouzman (Co-Chair), Dan Ord, Sophie Byrom, Adya Gupta and Esme de Villiers. The Youth Board members are working on developing a strategy for the next three years, and we thank all Youth Board Members, retired and current, for their insight and ideas which have been extremely valuable.

Risk management

The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT's charitable activities. A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.

Going concern

The Trustees consider there are no material uncertainties about the charitable company's ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.


Disclosure of information to auditor

Each trustee has taken steps that they ought to have taken as a trustee in order to make themselves aware of any relevant audit information and to establish that the charity's auditor is aware of that information. The trustees confirm that there is no relevant information that they know of and of which they know the auditor is unaware.

Small companies provision statement

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The annual report was approved by the trustees of the charity on 14 October 2025 and signed on their behalf by:



.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Statement of Trustees' Responsibilities


The trustees (who are also the directors of The Aplastic Anaemia Trust for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 14 October 2025 and signed on its behalf by:



.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Independent Auditor's Report to the Members of The Aplastic Anaemia Trust

Opinion

We have audited the financial statements of The Aplastic Anaemia Trust (the 'charity') for the year ended 31 March 2025, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is United Kingdom Accounting Standards, comprising Charities SORP - FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and applicable law (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

The Aplastic Anaemia Trust

Independent Auditor's Report to the Members of The Aplastic Anaemia Trust

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Trustees' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities (set out on page 15), the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below.

Our approach to identifying and assessing the risks of material misstatement respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charity through discussions with trustees and other management, and from our knowledge and experience of the charity sector;

The Aplastic Anaemia Trust

Independent Auditor's Report to the Members of The Aplastic Anaemia Trust

- we focussed on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charity, including the Charities Act 2011;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- we identified laws and regulations which were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures on material balances for which robust, substantive analytical procedures have been undertaken to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions; and
- investigated the rationale behind significant or unusual transactions.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of noncompliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its trustees as a body, for our audit work, for this report, or for the opinions we have formed.

The Aplastic Anaemia Trust

Independent Auditor's Report to the Members of The Aplastic Anaemia Trust



.....
Mark Heaton FCCA FCIE DChA (Senior Statutory Auditor)
For and on behalf of KM, Statutory Auditor

1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

Date:..... 14/10/21

The Aplastic Anaemia Trust

Statement of Financial Activities for the Year Ended 31 March 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2025 £	Unrestricted funds £	Restricted funds £	Total 2024 £
Income from:							
Donations and legacies	3	363,207	-	363,207	146,207	70,150	216,357
Grants receivable	4	-	250,621	250,621	19,940	212,011	231,951
Fund-raising events	5	24,379	-	24,379	22,779	-	22,779
Investment income	6	9,003	-	9,003	7,683	-	7,683
Total income		<u>396,589</u>	<u>250,621</u>	<u>647,210</u>	<u>196,609</u>	<u>282,161</u>	<u>478,770</u>
Expenditure on:							
Raising funds	7	(37,043)	-	(37,043)	(34,539)	-	(34,539)
Charitable activities	8	(332,188)	(224,562)	(556,750)	(190,337)	(275,449)	(465,786)
Total expenditure		<u>(369,231)</u>	<u>(224,562)</u>	<u>(593,793)</u>	<u>(224,876)</u>	<u>(275,449)</u>	<u>(500,325)</u>
Net income/(expenditure)		<u>27,358</u>	<u>26,059</u>	<u>53,417</u>	<u>(28,267)</u>	<u>6,712</u>	<u>(21,555)</u>
Net movement in funds		27,358	26,059	53,417	(28,267)	6,712	(21,555)
Reconciliation of funds							
Total funds brought forward		<u>301,851</u>	<u>116,712</u>	<u>418,563</u>	<u>330,118</u>	<u>110,000</u>	<u>440,118</u>
Total funds carried forward	18	<u><u>329,209</u></u>	<u><u>142,771</u></u>	<u><u>471,980</u></u>	<u><u>301,851</u></u>	<u><u>116,712</u></u>	<u><u>418,563</u></u>


All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2024 is shown in note 18.

The Aplastic Anaemia Trust
(Registration number: 05174065)
Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Current assets			
Debtors	14	44,064	21,686
Cash at bank and in hand		<u>526,862</u>	<u>522,970</u>
		570,926	544,656
Creditors: Amounts falling due within one year	15	<u>(62,635)</u>	<u>(73,193)</u>
Total assets less current liabilities		508,291	471,463
Creditors: Amounts falling due after more than one year	16	<u>(36,311)</u>	<u>(52,900)</u>
Net assets		<u>471,980</u>	<u>418,563</u>
Funds of the charity:			
Restricted income funds			
Restricted funds		142,771	116,712
Unrestricted income funds			
Unrestricted funds		<u>329,209</u>	<u>301,851</u>
Total funds	18	<u>471,980</u>	<u>418,563</u>

The financial statements on pages 20 to 30 were approved by the trustees, and authorised for issue on 14 October 2025 and signed on their behalf by:



.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Statement of Cash Flows for the Year Ended 31 March 2025

	Note	2025 £	2024 £
Cash flows from operating activities			
Net cash income/(expenditure)		53,417	(21,555)
Adjustments to cash flows from non-cash items			
Investment income	6	<u>(9,003)</u>	<u>(7,683)</u>
		44,414	(29,238)
Working capital adjustments			
Increase in debtors	14	(22,378)	(2,564)
Decrease in creditors	15	<u>(27,147)</u>	<u>(67,861)</u>
Net cash flows from operating activities		(5,111)	(99,663)
Cash flows from investing activities			
Interest receivable and similar income	6	<u>9,003</u>	<u>7,683</u>
Net increase/(decrease) in cash and cash equivalents		3,892	(91,980)
Cash and cash equivalents at 1 April		<u>522,970</u>	<u>614,950</u>
Cash and cash equivalents at 31 March		<u><u>526,862</u></u>	<u><u>522,970</u></u>

All of the cash flows are derived from continuing operations during the above two periods.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.

The address of its registered office is:

1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

These financial statements were authorised for issue by the trustees on 14 October 2025.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.

Basis of preparation

The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Income from donations

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General	funds	2025	2024
	£	£	£	£
Donations and legacies	363,207	-	363,207	216,357
	<u>363,207</u>	<u>-</u>	<u>363,207</u>	<u>216,357</u>

4 Income from charitable activities

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General	funds	2025	2024
	£	£	£	£
Grants receivable	-	250,621	250,621	231,951
	<u>-</u>	<u>250,621</u>	<u>250,621</u>	<u>231,951</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

5 Income from fund-raising

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General £			
Fund-raising events	24,379	-	24,379	22,779
	<u>24,379</u>	<u>-</u>	<u>24,379</u>	<u>22,779</u>

6 Investment income

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General £			
Interest receivable on bank deposits	9,003	-	9,003	7,683
	<u>9,003</u>	<u>-</u>	<u>9,003</u>	<u>7,683</u>

7 Expenditure on raising funds

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General £			
Fundraising staff costs	37,043	-	37,043	34,539
	<u>37,043</u>	<u>-</u>	<u>37,043</u>	<u>34,539</u>

8 Expenditure on charitable activities

	Note	Unrestricted funds	Restricted funds	Total 2025	Total 2024
		General £			
Patient Information, outreach & support		328,788	224,562	553,350	463,936
Governance costs	9	3,400	-	3,400	1,850
		<u>332,188</u>	<u>224,562</u>	<u>556,750</u>	<u>465,786</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

9 Analysis of governance and support costs

Governance costs

	Unrestricted funds	Restricted funds	Total 2025	Total 2024
	General £	£	£	£
Independent Examiner's remuneration	-	-	-	1,850
Audit of the financial statements	3,400	-	3,400	-
	<u>3,400</u>	<u>-</u>	<u>3,400</u>	<u>1,850</u>

10 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

£224 (2024: £Nil) of expenses in relation to travel were reimbursed to two trustees during the year.

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any other benefits from the charity during the year.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

11 Staff costs

The aggregate payroll costs were as follows:

	2025 £	2024 £
Staff costs during the year were:		
Wages and salaries	317,772	258,488
Social security costs	25,496	18,881
Pension costs	7,352	7,739
	<u>350,620</u>	<u>285,108</u>

The monthly average number of persons (including senior management team) employed by the charity during the year was as follows:

	2025 No	2024 No
Charitable activities	<u>11</u>	<u>10</u>

The number of employees whose emoluments fell within the following bands was:

	2025 No	2024 No
£60,001 - £70,000	-	1
£70,001 - £80,000	<u>1</u>	<u>-</u>

12 Auditors' remuneration

	2025 £	2024 £
Audit of the financial statements	<u>3,400</u>	<u>-</u>

13 Taxation

The charity is a registered charity and is therefore exempt from taxation.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

14 Debtors

	2025 £	2024 £
Trade debtors	-	159
Prepayments	13,793	7,677
Accrued income	30,041	13,850
Other debtors	230	-
	<u>44,064</u>	<u>21,686</u>

15 Creditors: amounts falling due within one year

	2025 £	2024 £
Research grant commitments	58,133	68,542
Pension scheme creditor	1,102	1,005
Accruals	3,400	3,646
	<u>62,635</u>	<u>73,193</u>

16 Creditors: amounts falling due after one year

	2025 £	2024 £
Research grant commitments	<u>36,311</u>	<u>52,900</u>

17 Pension and other schemes

Defined contribution pension scheme

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £7,352 (2024 - £7,739).

Contributions totalling £1,102 (2024 - £1,005) were payable to the scheme at the end of the year and are included in creditors.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

18 Funds

Current Year

	Balance at 1 April 2024 £	Incoming resources £	Resources expended £	Balance at 31 March 2025 £
Unrestricted funds				
General	301,851	396,589	(369,231)	329,209
Restricted funds				
National Lottery - Better Together	112,189	204,705	(208,312)	108,582
Contact a Family	4,523	-	(4,523)	-
Family Support	-	19,922	(4,306)	15,616
Children and Young People	-	10,994	(2,079)	8,915
Individualised Support Project	-	-	(5,342)	(5,342)
National Community Survey	-	15,000	-	15,000
	<u>116,712</u>	<u>250,621</u>	<u>(224,562)</u>	<u>142,771</u>
Total funds	<u><u>418,563</u></u>	<u><u>647,210</u></u>	<u><u>(593,793)</u></u>	<u><u>471,980</u></u>

Prior Year

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Unrestricted funds				
General	330,118	196,609	(224,876)	301,851
Restricted funds				
National Community Survey	-	70,000	(70,000)	-
National Lottery - Better Together	105,674	203,661	(197,146)	112,189
Contact a family	4,326	8,500	(8,303)	4,523
	<u>110,000</u>	<u>282,161</u>	<u>(275,449)</u>	<u>116,712</u>
Total funds	<u><u>440,118</u></u>	<u><u>478,770</u></u>	<u><u>(500,325)</u></u>	<u><u>418,563</u></u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2025

19 Analysis of net assets between funds

Current Year

	Unrestricted funds	Restricted funds	2025 Total funds
	General	funds	funds
	£	£	£
Current assets	428,155	142,771	570,926
Current liabilities	(62,635)	-	(62,635)
Creditors over 1 year	(36,311)	-	(36,311)
	<u>329,209</u>	<u>142,771</u>	<u>471,980</u>
Total net assets	<u>329,209</u>	<u>142,771</u>	<u>471,980</u>

Prior Year

	Unrestricted funds	Restricted funds	2024 Total funds
	General	funds	funds
	£	£	£
Current assets	427,944	116,712	544,656
Current liabilities	(73,193)	-	(73,193)
Creditors over 1 year	(52,900)	-	(52,900)
	<u>301,851</u>	<u>116,712</u>	<u>418,563</u>
Total net assets	<u>301,851</u>	<u>116,712</u>	<u>418,563</u>

THE APLASTIC ANAEMIA TRUST

England & Wales - Charity number 1107539

Accounts

Company registration number: 05174065

Charity registration number: 1107539

Charity number (Scotland): SC049810



**the
aplastic
anaemia
trust**

The Aplastic Anaemia Trust

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2024

KM
Chartered Accountants
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

The Aplastic Anaemia Trust

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 11
Independent Examiner's Report	12 to 13
Statement of Financial Activities	14
Balance Sheet	15
Notes to the Financial Statements	16 to 22

The Aplastic Anaemia Trust

Reference and Administrative Details

Chair	A Conquy
Trustees	J Beart A Conquy J L Cozens S Gilbert S Oliver T Stephenson C Tempest J Williamson
Secretary	S L Tyler
Principal Office	1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
Company Registration Number	05174065
Charity Registration Number	1107539
Charity Registration Number Scotland	SC049810
Bankers	CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 5JQ
Independent Examiner	KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG

The Aplastic Anaemia Trust

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2024.

Trustees

J Beart

A Conquy

J L Cozens

S Gilbert

S Oliver

T Stephenson

C Tempest

J Williamson

Introduction

This has been a year of embedding processes and systems delivery for The Aplastic Anaemia Trust. Despite tough economic times, the organisation was able to hit the revised fundraising target of £150k. We are very grateful for the efforts of our community in continuing to fundraise and support us during these difficult times.

We implemented a new structure for our online support groups, by treatment type and stage which has led to more engaged and bigger groups.

The cost of living crisis and the current strain on health services has exacerbated many of the difficulties of living with an ultra-rare condition, with our community reporting longer waiting times and more challenges accessing benefits support. We remain grateful for our strategic partnership with Maggie's Cancer Care, through whom we are able to offer welfare benefits advice.

The Better Together For Healthy Marrow Partnership has been a huge benefit for the AAT community and is now approaching the half way point of its three year funding.

We work together to deliver improved support for our communities - people affected by a range of related rare bone marrow failures that are not caused by cancer.

The six small but mighty organisations in this partnership are:

- The Aplastic Anaemia Trust
- CAN (Congenital Anaemia Network)
- DC Action
- Fanconi Hope
- PNH Support
- SDS UK

This year we have focused on providing excellent psychological and emotional support in the form of courses, as well as 1-1 provision.

As a small charity who strive always to punch above our weight, strong partnerships are key to our organisational strategy. This approach is enabling us to deliver both support and research more effectively and at a higher quality than we could achieve alone.

The Aplastic Anaemia Trust

Trustees' Report

This year we have developed signposting and information sharing partnerships with Young Lives vs Cancer and Teenage Cancer Trust. We have also worked with Leukaemia Care, who have retired their Aplastic Anaemia leaflet after contacting us about how impressive our information services are and that they no longer need to fill this gap.

Underpinning the core aims in our strategy is the aim to better understand the needs of people affected by aplastic anaemia. We took great strides this year, with the launch of our Rare Voices Report, which is the publication of the results of our National Community Survey. and put a real focus on improving the monitoring and evaluation of the work that we deliver. Through the Better Together for Healthy Bone Marrow project, funded by The National Lottery, we are now working with Consultant Emma Insley to track the impact of our work on the lives of people affected by aplastic anaemia.

Objectives and Activities

What is Aplastic Anaemia?

Aplastic anaemia is a rare and life-threatening form of bone marrow failure. It can affect people of any age, but it is most common in children and older people. The majority of cases are acquired, but many of our community are also diagnosed with inherited types of aplastic anaemia. The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every person diagnosed with aplastic anaemia and their loved ones, to help relieve the immense disease burden. We estimate 150 to 250 people per year are diagnosed with AA - there is no registry collecting this information at the moment so it is impossible to give an accurate number. However we know from our clinical networks that this figure is on the rise in adults and children. The AAT has ambitions to fund the first AA registry in 2024.

Our Mission, Vision and Objectives

The objects of the charity as defined in its Articles of Association are to relieve the sickness of those people suffering from bone marrow disease.

Vision

Everyone affected by aplastic anaemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.

Mission

We deliver our vision through two key strategies:

1. Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
2. Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.

The Aplastic Anaemia Trust

Trustees' Report

Our strategic objectives

- A. Ensure everyone affected by aplastic anaemia has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.
- B. Improve the knowledge and understanding of aplastic anaemia through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.
- C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes.
- D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.

Our fundraising acts as an enabler in our strategy, ensuring we have the resources to deliver these objectives.

Challenges of 2023/24

This year we have put a focus on creating our wonderful Rare Voices report, the first national survey of rare bone marrow failures and the needs and experiences of those affected. Over four hundred people participated, giving us a clear view of their needs. We took the first steps in responding to these needs.

The key themes were and continue to be:

- Mental Health and Wellbeing
- Navigating the system
- Practical Support
- Raising awareness

An overstretched NHS and uncertainty about Rare Disease Strategy

Aplastic anaemia is an ultra-rare condition, and as the UK health system faced a turbulent year, with services overstretched, our work to support patients and their families has never been more important. Pressures of particular concern for aplastic anaemia patients include the widely-reported rise in the length of time that patients have been waiting for emergency, routine and cancer treatments which we hear frequently applies to our community too. For example, while we do not have access to data for aplastic anaemia specifically, we know that the number of patients seen by a specialist consultant within two weeks of an urgent GP referral for suspected cancer remains well below target. The 93% performance target for patients to be seen within that time frame has not been met since May 2020. In May 2023, this stood at 80.8%

Whilst we welcome the launch of the Rare Disease Framework and the opportunity to participate in discussions around the future of care commissioning, we remain concerned about the move away from centralised care to Integrated Care Boards (ICBs) and what these mean for accessing expertise for rare diseases. As part of our work with Better Together, we have been writing to key NHS and Clinical Commissioning Group (CCG) members inviting them to discuss this with us.

What did people affected by Aplastic Anaemia need in 2023?

We have seen a significant increase in the number of people contacting us for support, whether by phone, email, or interacting via our private Facebook Support Group. In 2023-24, we provided support to 312 individuals, compared to 268 individuals in 2022-23. This represents a 16% increase in demand for and access to the support that we offer.

The Aplastic Anaemia Trust

Trustees' Report

Regardless of the stage in their treatment journey at which a person affected by aplastic anaemia reaches out to us, we are often in contact with our community members on numerous occasions throughout their journey - indeed, it is very unusual for a person to only reach out to us for support on one occasion. In 2023-24, we recorded a total of 867 support 'interactions' with people that reached out to us, whether that be answering a question via email or phone or signposting them to a specialist to support them with their financial or emotional wellbeing. In 2022-23, the total number of 'interactions' recorded was 597, which shows, once again, that we have seen a significant increase in demand for our services this year, and that we are fostering long-term relationships, enabling us to support people in the longer-term through their diagnosis and treatment. These figures show that we have seen a 45% increase this year in the number of interactions we have with those that we support, compared to 2022-23.

A diagnosis of aplastic anaemia can be incredibly debilitating and impacts every aspect of daily life. In these challenging times, our patient community continues to experience financial challenges, whether related to the ongoing cost of living crisis, or difficulties in accessing, or navigating the welfare benefits system. Although we have seen fewer requests for support around benefits this year (21 requests for benefits consultations in 2023-24, compared to 23 requests made in 2022-23), we frequently hear from our community about the financial issues and pressures that they face, often exacerbated by issues in applying for benefits such as PIP, where claims are frequently rejected, with our community members having to go through the mandatory consideration and tribunal processes in order to access the benefits that they are entitled to. In turn, this creates an additional practical and psychological burden for those affected by aplastic anaemia, further exacerbating an already difficult situation.

Difficult times for fundraising

The cost of living crisis has potential to significantly impact the quality of life and mental wellbeing of members of our community, and also poses a risk to our organisation's income - as we are proud to receive over a third of our funding from community fundraising.

Achievements and performance highlights

How The AAT delivered public benefit in 2023/2024

The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.

In line with the governing document, the Memorandum and Articles of Association, our performance highlights for the last year in relation to the Charity's aims are set out below.

Delivering support

Our small and agile Support and Outreach team are swift to adapt to the evolving needs of aplastic anaemia patients in a rapidly changing world. Investment in the project management of this team has seen these abilities strengthened, as the online services we developed during lockdown are iterated and expanded into in-person support.

This year our support team and small group of dedicated volunteers:

- Delivered 9 informative webinars. These webinars connected people affected by aplastic anaemia with global experts speaking about specific aspects of living with the condition, or they were delivered by a psychologist with the intention of offering emotional wellbeing support to those living with the conditions or those supporting people who are living with the conditions.

The Aplastic Anaemia Trust

Trustees' Report

- Streamlined the provision of our support packs for children in hospitals and their siblings left at home, in collaboration with our Youth Board. These include a handmade blanket, a tablet to enable them to access our online resources and a bespoke activity book designed by our Youth Board to support a child's mental wellbeing.
- Continued and extended our bespoke service to provide our expert support to even more families, including parents, children, siblings, grandparents and wider family networks.
- Launched a new Mindfulness for Stress Course to sit alongside the popular Managing Stress Course, designed and delivered by Maggie's psychologists to deliver expert mental health and resilience support to small groups.
- In collaboration with our community reference group (our volunteer patient feedback group) and Maggie's psychologists, co-designed a new course entitled 'Moving Forward: Living the life that matters to you' designed specifically for those people moving on from active treatment. This will be launched during the next financial year.
- Delivered our Winter Wellness programme offering our community various support options to help them through the specific challenges of the winter season including making seasonal befriending calls to more isolated members of our community.
- Continued to facilitate and moderate daily discussion in our active Patient Support Facebook Group.
- Held coffee mornings in Leeds, Glasgow, Edinburgh and a plan for expanding this to Birmingham is also underway.
- Delivered our 6 popular monthly online meet-ups which are focused on specific journey stages, enabling patients and their families to connect with others at the same stage of their journey.
- Delivered our AAT online book club, to help bring our community together in a fun and engaging activity, without the focus being on illness.
- Continued to offer one to one support via messenger, email, support line calls and WhatsApp as preferred by the individual community member.
- Arranged in-person visits with patients either in hospital or otherwise unable to attend the in-person coffee mornings
- Held a Sepsis Awareness Campaign in collaboration with the UK Sepsis Trust with regular orders of the co-designed sepsis alert cards being made and one of our Youth Board members sharing their experience of sepsis with aplastic anaemia with the UK Sepsis Trust.
- Our Youth Board has evolved with three new members joining, bringing new insights and valuable perspectives, with an older member retiring. The Youth Board continued to offer their voice to ensure that the Support & Outreach team always considers the needs of young people with aplastic anaemia.
- Built on our organisational connections, working with Maggie's, the Teenage Cancer Trust, Young Lives vs Cancer, Anthony Nolan, Over the Wall and our Better Together partners.
- Mapped our customer journeys and identified key 'touchpoints' to allow us to offer our community more personalised support.

The Aplastic Anaemia Trust

Trustees' Report

Building partnerships and Better Together for Healthy Marrow

Building successful partnerships is at the heart of our organisational strategy, and this year has seen very positive results from this approach. We are now halfway through the three-year National Lottery Community Fund project 'Better Together for Healthy Bone Marrow'.

Our most significant progress has been in relation to our emotional wellbeing framework, which is now delivering an ongoing programme of webinars and courses as well as tailored one-to-one support from our Psychology Team. Across our six communities, 219 people have accessed these provisions so far.

Better Together has so far delivered:

- Six webinars, attended by 97 people
- Four Managing Stress & Uncertainty courses, accessed by 80 people
- Three Mindfulness courses, attended by 25 people
- One-to-one support from the Psychology Team for 17 people

Our collaborative fundraising campaign has raised £56,860 across our six charities. We have created a comprehensive social media campaign, building on our Rare Voices report findings, shining a spotlight on community identified needs.

Our partnership with Maggie's remains a vital and powerful one. At Leeds Hospital, a key hub of expertise for aplastic anaemia, we have now established weekly face-to-face aplastic anaemia coffee mornings at the Maggie's centre there. Zoe from our team is working with Maggie's to provide joined up support that ensures people diagnosed with aplastic anaemia in Leeds have the same access to the warm, expert Maggie's support provided to cancer patients - plus the connection to other aplastic anaemia patients and rare disease understanding, direct from the AAT. In 24/25 we intend to develop this model in Scotland and Birmingham .

We are working with Contact, a charity for families with disabled children, to use funding from the Pears Foundation to deliver a specific support programme for families affected by aplastic anaemia. We are proud to report that 140 people have benefitted from the Family Support Project this year. This figure includes children, siblings, cousins, a grandparent, carers and parents.

Research Highlights

Trialling new treatment

The TIARA Trial at King's, which The Aplastic Anaemia Trust is co-funding with LifeArc, experienced delays during the pandemic, so it was fantastic news this year to see the first aplastic anaemia patients in the world receive T regulatory cells as a potential new treatment for the condition.

Key findings:

King's College Hospital showed that the Treg cells are reduced in aplastic anaemia. Furthermore, outside the patient's body these cells are expandable and functionally competent in suppressing cellular responses that are directly or indirectly associated with the destruction of bone marrow stem cells.

This led the Kings team to devise a world first Phase 1 MHRA approved trial that involves taking the T cells from specific patients with AA, identifying and expanding the Tregs under good manufacturing practices and infusing two doses, two weeks apart of these cells. Thus far 6 patients have received both doses of expanded Treg cells. The treatment appears to be extremely well tolerated and there have not been any safety concerns.

Response signals are currently being evaluated in detail using clinical and translational research criteria. It is hoped the data will be mature for presentation at the American Society of Haematology 2024 meeting in San Diego.

The Aplastic Anaemia Trust

Trustees' Report

Building a registry for children with AA

Following commitment of funding by The AAT for a three year period, recruitment for our paediatric UK bone marrow failure registry and biobank was completed in June. 45 children with idiopathic Severe Aplastic Anaemia have been recruited over a three-year period, in a project led by Dr Sujith Samarasinghe, Great Ormond Street Hospital, London.

This project has now closed.

We are pleased to announce that the registry came in under cost by £30k. This has allowed us to reinvest the money in other clinical research projects (see below).

Genomic Sequencing to understand Mutation timing and clonal trajectories in aplastic anaemia.

We funded a portion of the costs for a study into Mutation timing and clonal trajectories in aplastic anaemia. This research project brings together researchers from Leeds, Cambridge and the Sangar Institute working in partnership to investigate the genes of people with aplastic anaemia as a first step to find ways to better predict treatment responses and later complications, such as cancer.

Funding new research

This year, because of the underspend on the paediatric bone marrow registry project, we were able to commit £36k to funding the first bone marrow registry for people with AA, for those who receive transplants and those who don't. This is in collaboration with EBMT and BSBMTCT. We hope to get the project kicked off Summer 2024. This is a vital piece of work because we currently have no clinical data on how many people are newly diagnosed each year, and what proportion of those people receive transplants vs therapeutic or drug therapies. It also limits the kind of research than can be done to understand this condition, for example the long term health outcomes or whether it leads to other diseases or co-morbidities later in life.

Fundraising Highlights

This was the second year of running our annual Super Rare campaign, with the six other small organisations in the Better Together partnership fundraising alongside us. Despite the challenging fundraising environment, our community stepped up - and Super Rare hit target for The Aplastic Anaemia Trust, raising £24,038 against a target of £20,000 for our charity, making March our most successful month of the year. A total of £56,870 was raised across all the charity partners during Super Rare 2024.

2023 was a tough climate for fundraising, with more economic uncertainty and people feeling the pinch of the cost-of-living crisis. We are so proud of our supporters, who managed to maintain their level of fundraising and generosity of giving, with the individual giving coming in at the same average amount as in previous years. The tough fundraising conditions' impact was felt more keenly by us this year as it was compounded by the lack of a large single event, or single large gift, during the period.

- Our Santa Splash event is going from strength to strength, with 130 people in 4 locations for 2023, and £5300 raised.
- The Great North Run is proving to be our biggest running event, where 17 people took part raising £9,500
- Our walking events remain vital chances for our community to meet up, with the Peak District Walk having 53 people attend, and raising £3100.
- The Big Give was trialled for the first time, where we raised £2,500 in pledges and which was matched by a further £2,500 during the appeal. This was then doubled. A big success.

The Aplastic Anaemia Trust

Trustees' Report

We thank the following Trusts, Foundations and organisations for their funding and support this year:

The Stafford Trust
The Meikle Foundation
The National Lottery Community Fund
The David and Rosemary Philips Trust
Contact a Family and the Pears Foundation
The Hospital Saturday Fund via the Big Give

Risk management

The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT's charitable activities.

A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.

Going Concern

The Trustees consider there are no material uncertainties about the charitable company's ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.

Financial Review

How our income and expenditure changed in 2023/2024

Unrestricted income for the year totalled £196,609 (22/23: £193,950) and expenditure amounted to £224,875 (22/23: £307,484) resulting in a net deficit on unrestricted funds for the year of £28,267 (22/23: £113,534). Restricted income of £282,161 was received in the year (22/23: £280,350). Expenditure incurred and charged against restricted income funds amounted to £275,449 (22/23: £173,921), leaving balances on restricted funds totalling £116,712 at 31 March 2024 (22/23: £110,000).

Managing our income across a range of rare bone marrow failures

As we move into the second year of funding complex partnership projects, it is useful to note with these accounts that the grant income from The National Lottery Community Fund represents budget which is managed by The Aplastic Anaemia Trust to deliver work that is designed to benefit our Better Together partnership of six small organisations (listed above), and the communities of people that all seven organisations represent. This project falls within The Aplastic Anaemia Trust's charitable objectives of supporting people suffering from bone marrow disease and by working collaboratively with partnership organisations who are expert in their specific conditions, we can replicate benefits and learning across all our organisations and speak with one voice.

This demonstrates a strategic and forward-thinking approach to having impact in the field of bone marrow failure as per our charitable purpose.

The Aplastic Anaemia Trust

Trustees' Report

Our reserves position and policy update

The ongoing challenge we face is how to be sure of sustainable funding for these essential support services, while also being able to invest in research.

In response, our reserves policy remains as 22/23 - to ensure we hold 9 months core operating costs in unrestricted reserves, so that the charity will be able to maintain vital services and re-establish our income, should one source of income drop unexpectedly. Our reasoning, method of calculating required funds, and the purpose for retaining these reserves is outlined in our reserves policy.

The nine months of core operating costs will be recalculated annually. As at March 2024 we calculated that the target figure should be £217k and unrestricted reserves stand at £302k (£85k above target). Our unrestricted reserves position has allowed us to invest and grow our Support & Outreach offer, and now we need to ensure that our annual income allows the offer to be sustainable. We took the decision reduce reserves over two years, to allow time for the income growth we expect and to manage the current financial uncertainty, and by March 2026 expect to have reduced unrestricted reserves to our target.

Our priority for the next financial year is to continue to seek funding to cover the costs of work delivered by our support team, which will provide confidence that our current level of support is sustainable and enable us to invest future income raised by community fundraising in research partnership projects. This budget does not include investment in new research projects; however we will be investing in some expert fundraising resource to run a feasibility study on the research funding landscape, and to establish whether the AAT should be investing in this area of fundraising as an additional budgeted income stream over and above the current financial framework.

Pharmaceutical Industry income in 2023/2024

Following the excellent relationship building we did in 22/23, where we received support from Sobi, Roche and Alexion AstraZeneca Rare Disease to fund the National Community Survey, we have been able to use the Rare Voices report to open further conversations about how to support the needs of our community going forward. In the last year we were pleased to receive sponsorship from Sobi, Alexion AstraZeneca Rare Disease, Roche and Pfizer towards the Rare Voices report and campaign.

Sobi also provided grant funding for our Winter Wellness programme, enabling us to deliver enhanced support to our communities over winter, a time when the isolation and anxiety experienced by many of our community are exacerbated by heightened worries about seasonal infections among those who are immunocompromised, and missing out on seasonal festivities.

This support forms part of our balanced income portfolio, limiting the total income from pharmaceutical companies to one third.

Structure, Governance and Management

Embedding our board

Following our board skills audit and the subsequent expansion of the board in 22/23 we have focused on embedding the trustees into the organisation through offering training and attendance at staff conferences. Jane Cozens became our Vice Chair and we have highly functioning finance sub-committees supporting the governance of the AAT. We feel well placed to support the bigger and more complex organisation it has become.

The Aplastic Anaemia Trust

Trustees' Report

Research and Clinical Advisory Panel and Youth Board

Our Research and Clinical Advisory Panel welcomed Professor Rod Skinner into his role as Vice Chair. The rest of the board remains the same and we thank them for their ongoing service.

There were also changes to our Youth Board. Ashleigh Kennedy left the board during this year, having simply reached too great an age (i.e. over 25 years old) to sit on the panel. We were pleased to welcome three new members, India Wyldbore-Smith, Sophie Ouzman and Daisy Hall which brings the Youth Board membership up to a total of seven at the end of the year. The Youth Board members are working on developing a strategy for the next three years, and we thank all Youth Board Members, retired and current, for their insight and ideas which have been extremely valuable.

Chief Executive


Our Chief Executive, Stevie Tyler, returned from Maternity Leave on November 2023. Our Head of Comms and Fundraising, Ellie Dawes, stepped up as Acting CEO while Stevie is away, and did an excellent job of managing the running of the organisation.

The Trustees have delegated day-to-day management of the Trust's affairs to Stevie Tyler

Small companies provision statement

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The annual report was approved by the trustees of the charity on 31 October 2024 and signed on their behalf by:



A Conquy
Trustee

Type text here

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2024 which are set out on pages 14 to 22.

Respective responsibilities of trustees and examiner

As the company's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and eligible for independent examination, I report in respect of my examination of the company's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since The Aplastic Anaemia Trust's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Charity Independent Examiners, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust



.....
Mark Heaton FCCA FCIE DChA

KM

1st Floor, Block C

The Wharf

Manchester Road

Burnley

Lancashire

BB11 1JG

31 October 2024

The Aplastic Anaemia Trust

Statement of Financial Activities for the Year Ended 31 March 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2024 £	Unrestricted funds £	Restricted funds £	Total 2023 £
Income from:							
Donations and legacies	3	146,207	70,150	216,357	147,763	70,000	217,763
Grants receivable	4	19,940	212,011	231,951	-	210,350	210,350
Fund-raising events	5	22,779	-	22,779	43,450	-	43,450
Investment income	6	7,683	-	7,683	2,737	-	2,737
Total income		<u>196,609</u>	<u>282,161</u>	<u>478,770</u>	<u>193,950</u>	<u>280,350</u>	<u>474,300</u>
Expenditure on:							
Raising funds	7	(34,539)	-	(34,539)	(26,047)	-	(26,047)
Charitable activities	8	(190,337)	(275,449)	(465,786)	(281,437)	(173,921)	(455,358)
Total expenditure		<u>(224,876)</u>	<u>(275,449)</u>	<u>(500,325)</u>	<u>(307,484)</u>	<u>(173,921)</u>	<u>(481,405)</u>
Net (expenditure)/income		<u>(28,267)</u>	<u>6,712</u>	<u>(21,555)</u>	<u>(113,534)</u>	<u>106,429</u>	<u>(7,105)</u>
Net movement in funds		(28,267)	6,712	(21,555)	(113,534)	106,429	(7,105)
Reconciliation of funds							
Total funds brought forward		<u>330,118</u>	<u>110,000</u>	<u>440,118</u>	<u>443,652</u>	<u>3,571</u>	<u>447,223</u>
Total funds carried forward	18	<u><u>301,851</u></u>	<u><u>116,712</u></u>	<u><u>418,563</u></u>	<u><u>330,118</u></u>	<u><u>110,000</u></u>	<u><u>440,118</u></u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2023 is shown in note 18.

The Aplastic Anaemia Trust
(Registration number: 05174065)
Balance Sheet as at 31 March 2024

	Note	2024 £	2023 £
Current assets			
Debtors	14	21,686	19,122
Cash at bank and in hand		522,970	614,950
		544,656	634,072
Creditors: Amounts falling due within one year	15	(73,193)	(145,709)
Total assets less current liabilities		471,463	488,363
Creditors: Amounts falling due after more than one year	16	(52,900)	(48,245)
Net assets		418,563	440,118
Funds of the charity:			
Restricted income funds			
Restricted funds		116,712	110,000
Unrestricted income funds			
Unrestricted funds		301,851	330,118
Total funds	18	418,563	440,118


For the financial year ending 31 March 2024 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476. However, in accordance with section 44 of the Charities and Trustee Investment (Scotland) Act 2005, the accounts have been examined by an independent examiner whose report appears on page 12; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 14 to 22 were approved by the trustees, and authorised for issue on 31 October 2024 and signed on their behalf by:



.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.

The address of its registered office is:

1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

These financial statements were authorised for issue by the trustees on 31 October 2024.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.

Basis of preparation

The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity is exempt from preparing a cash flow statement.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Income from donations

	Unrestricted funds	Restricted funds	Total 2024	Total 2023
	General £	£	£	£
Donations and legacies	146,207	70,150	216,357	217,763
	<u>146,207</u>	<u>70,150</u>	<u>216,357</u>	<u>217,763</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

4 Income from charitable activities

	Unrestricted funds	Restricted funds	Total 2024	Total 2023
	General £	£	£	£
Grants receivable	19,940	212,011	231,951	210,350
	<u>19,940</u>	<u>212,011</u>	<u>231,951</u>	<u>210,350</u>

5 Income from fund-raising

	Unrestricted funds	Total 2024	Total 2023
	General £	£	£
Fund-raising events	22,779	22,779	43,450
	<u>22,779</u>	<u>22,779</u>	<u>43,450</u>

6 Investment income

	Unrestricted funds	Total 2024	Total 2023
	General £	£	£
Interest receivable and similar income; Interest receivable on bank deposits	7,683	7,683	2,737
	<u>7,683</u>	<u>7,683</u>	<u>2,737</u>

7 Expenditure on raising funds

	Unrestricted funds	Total 2024	Total 2023
	General £	£	£
Fundraising staff costs	34,539	34,539	26,047
	<u>34,539</u>	<u>34,539</u>	<u>26,047</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

8 Expenditure on charitable activities

		Unrestricted funds	Restricted funds	Total 2024	Total 2023
	Note	General £	£	£	£
Patient Information, outreach & support		188,487	275,449	463,936	397,662
Research & grants		-	-	-	55,946
Governance costs	9	1,850	-	1,850	1,750
		<u>190,337</u>	<u>275,449</u>	<u>465,786</u>	<u>455,358</u>

9 Analysis of governance and support costs

Governance costs

	Unrestricted funds	Total 2024	Total 2023
	General £	£	£
Independent Examiner's remuneration	1,850	1,850	1,750
	<u>1,850</u>	<u>1,850</u>	<u>1,750</u>

10 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

11 Staff costs

The aggregate payroll costs were as follows:

	2024 £	2023 £
Staff costs during the year were:		
Wages and salaries	258,488	207,524
Social security costs	18,881	19,037
Pension costs	7,739	4,816
	<u>285,108</u>	<u>231,377</u>

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2024 No	2023 No
Charitable activities	<u>10</u>	<u>9</u>

The number of employees whose emoluments fell within the following bands was:

	2024 No	2023 No
£60,001 - £70,000	<u>1</u>	<u>1</u>

12 Independent examiner's remuneration

	2024 £	2023 £
Examination of the financial statements	<u>1,850</u>	<u>1,750</u>

13 Taxation

The charity is a registered charity and is therefore exempt from taxation.

14 Debtors

	2024 £	2023 £
Trade debtors	159	-
Prepayments	7,677	-
Accrued income	<u>13,850</u>	<u>19,122</u>
	<u>21,686</u>	<u>19,122</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

15 Creditors: amounts falling due within one year

	2024 £	2023 £
Research grant commitments	68,542	135,198
Pension scheme creditor	1,005	-
Accruals	3,646	10,511
	73,193	145,709

16 Creditors: amounts falling due after one year

	2024 £	2023 £
Research grant commitments	52,900	48,245

17 Pension and other schemes

Defined contribution pension scheme

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £7,739 (2023 - £4,816).

Contributions totalling £1,005 (2023 - £Nil) were payable to the scheme at the end of the year and are included in creditors.

18 Funds

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Unrestricted funds				
General	330,118	196,609	(224,876)	301,851
	330,118	196,609	(224,876)	301,851
Restricted funds				
National Community Survey	-	70,000	(70,000)	-
National Lottery - Better Together	105,674	203,661	(197,146)	112,189
Contact a Family	4,326	8,500	(8,303)	4,523
	110,000	282,161	(275,449)	116,712
Total funds	440,118	478,770	(500,325)	418,563

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2024

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Unrestricted funds				
General	443,652	193,950	(307,484)	330,118
	<u>443,652</u>	<u>193,950</u>	<u>(307,484)</u>	<u>330,118</u>
Restricted funds				
National Lottery - Better Together	-	191,906	(86,232)	105,674
Contact a family	-	8,500	(4,174)	4,326
Awards For All	3,571	-	(3,571)	-
Winter Wellness Project	-	19,944	(19,944)	-
National Community Survey	-	60,000	(60,000)	-
	<u>3,571</u>	<u>280,350</u>	<u>(173,921)</u>	<u>110,000</u>
Total funds	<u><u>447,223</u></u>	<u><u>474,300</u></u>	<u><u>(481,405)</u></u>	<u><u>440,118</u></u>

19 Analysis of net assets between funds

	Unrestricted funds		Restricted funds	2024 Total funds £
	General £	£		
Current assets	427,944	116,712		544,656
Current liabilities	(73,193)	-		(73,193)
Creditors over 1 year	(52,900)	-		(52,900)
Total net assets	<u>301,851</u>	<u>116,712</u>		<u>418,563</u>
	Unrestricted funds		Restricted funds	2023 Total funds £
	General £	£		
Current assets	524,072	110,000		634,072
Current liabilities	(145,709)	-		(145,709)
Creditors over 1 year	(48,245)	-		(48,245)
Total net assets	<u>330,118</u>	<u>110,000</u>		<u>440,118</u>

THE APLASTIC ANAEMIA TRUST

England & Wales - Charity number 1107539

Accounts

Company registration number: 05174065

Charity registration number: 1107539

Charity number (Scotland): SC049810

The Aplastic Anaemia Trust

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2023

KM
Chartered Accountants
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

The Aplastic Anaemia Trust

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 10
Independent Examiner's Report	11 to 12
Statement of Financial Activities	13
Balance Sheet	14
Notes to the Financial Statements	15 to 21

The Aplastic Anaemia Trust

Reference and Administrative Details

Chair	A Conquy
Trustees	J Beart A Conquy J L Cozens S Gilbert S Oliver T Stephenson C Tempest J Williamson
Secretary	S L Tyler
Principal Office	1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
Company Registration Number	05174065
Charity Registration Number	1107539
Charity Registration Number Scotland	SC049810
Bankers	CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 5JQ
Independent Examiner	KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG

The Aplastic Anaemia Trust

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2023.

Trustees

J Beart (appointed 31 August 2022)

A Conquy

P M Cossell (resigned 6 December 2022)

J L Cozens

S Gilbert (appointed 31 August 2022)

S Moos (resigned 6 December 2022)

S Oliver (appointed 30 November 2022)

T Stephenson

C Tempest (appointed 31 August 2022)

J Williamson (appointed 16 February 2023)

Introduction

This year The Aplastic Anaemia Trust has shown that growing our team over the previous two years has enhanced our ability to understand and to react quickly to the evolving needs of people affected by aplastic anaemia (patients and the people close to them) in a rapidly changing world. It has been a year of iterative improvements in both our support and fundraising offerings, thanks to investment in a project manager role in the Support and Outreach team. A fresh look at our online support groups and psychological support in a post-lockdown environment has led to significant improvements to the ways we support our community.

The cost of living crisis and the current strain on health services has exacerbated many of the difficulties of living with an ultra-rare condition. We are very grateful for the efforts of our community in continuing to fundraise and support us during these difficult times.

As a small charity who strive always to punch above our weight, strong partnerships are key to our organisational strategy. This approach is enabling us to deliver both support and research more effectively and at a higher quality than we could achieve alone. With the launch of the Better Together for Healthy Marrow Project this year, leveraging partnerships means we're also delivering considerable societal benefit across other related or similar rare bone marrow related conditions.

Underpinning the core aims in our strategy is the aim to better understand the needs of aplastic anaemia patients. We took great strides this year, with the launch of our National Community Survey of people living with a rare condition related to bone marrow, and put a real focus on improving the monitoring and evaluation of the work that we deliver. Through the Better Together for Healthy Bone Marrow project, funded by The National Lottery, we are now working with Consultant Emma Insley to track the impact of our work in the lives of people affected by aplastic anaemia.

The Aplastic Anaemia Trust

Trustees' Report

Objectives and Activities

What is Aplastic Anaemia?

Aplastic anaemia is a rare and life-threatening form of bone marrow failure. It can affect people of any age, but it is most common in children and older people.

The majority of cases are acquired, but many of our community are also diagnosed with inherited types of aplastic anaemia. The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every person diagnosed with aplastic anaemia and their loved ones, to help relieve the immense disease burden.

Our Mission, Vision and Objectives

The objects of the charity as defined in its Articles of Association are to relieve the sickness of those people suffering from bone marrow disease and immune defects.

Vision

Everyone affected by aplastic anaemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.

Mission

We deliver our vision through two key strategies:

- Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
- Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.

Our strategic objectives

- A. Ensure everyone affected by aplastic anaemia has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.
- B. Improve the knowledge and understanding of aplastic anaemia through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.
- C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes.
- D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.

Our fundraising acts as an enabler in our strategy, ensuring we have the resources to deliver these objectives.

Challenges of 22/23

This year we have put a focus on identifying and adapting to the evolving needs of people affected by rare bone marrow failure. Aplastic anaemia is an ultra-rare condition, and as the UK health system faced a turbulent year, with services overstretched, our work to support patients and their families has never been more important.

An overstretched NHS

A recent report by the British Medical Association outlines some of the pressures in the NHS as we emerge from the Covid-19 pandemic:

“The NHS is experiencing some of the most severe pressures in its 75-year history. The COVID-19 pandemic is just the tip of the iceberg - the health service has been facing years of inadequate planning and chronic under-resourcing.” - *An NHS under pressure, The British Medical Association*

The Aplastic Anaemia Trust

Trustees' Report

Pressures of particular concern for aplastic anaemia patients include a reported rise in the length of time that patients have been waiting for emergency, routine and cancer treatment. For example, while we do not have access to data for aplastic anaemia specifically, we know that the proportion of patients seen by a specialist consultant within two weeks of an urgent GP referral for suspected cancer remains well below target. The 93% performance target for patients to be seen within that time frame has not been met since May 2020. In May 2023, this stood at 80.8%.

Delayed patient presentation during the pandemic and ongoing strain on GPs (the average number of patients per full-time equivalent GP has increased by 15% since 2015, according to data provided by the BMA), which could further contribute to delays to diagnosis, as patients struggle to get a GP appointment, or decide to put off seeing a doctor when showing early symptoms.

The awareness of ongoing issues in the NHS is high among the general public, which contributes to increased anxiety among our community, particularly with planned strikes over the next year.

Beyond Lockdown - the evolving needs of aplastic anaemia patients

Covid-19 continued to cast a shadow for some members of our community. At the start of the year, we received reports of aplastic anaemia patients struggling to get access to antiviral and monoclonal antibody treatment for Covid-19. Our support team ensured that these issues were raised with our strategic partners such as the Blood Cancer UK Vaccine Taskforce, and the Specialised Health Care Alliance, and provided tailored advice to help individuals gain access to this treatment.

The removal of all Covid-19 restrictions in Spring 2022 caused significant worries for vulnerable members of our community, and we were there to support them through this particularly stressful time. The results of the research we funded in 21/22, which revealed the efficacy of the Covid-19 vaccine for aplastic anaemia patients, provided reassurance for many.

Over the year, however, Covid-19- related queries made up just 6% of support enquiries, compared with 21% in the previous year. As many people in our community returned to some sense of normal life, enquiries related to what we call 'lifestyle'- related topics increased by 8% - including concerns about travel, social life, education and work.

The total number of people supported directly via one-to-one conversations remained steady - 268 individuals reached out to us for direct support in 2022-23, compared to 266 in 2021-22. However, people were turning to us more frequently - the total number of support 'interactions' increased by 10%.

A diagnosis of aplastic anaemia can hit families hard financially, and as the UK's cost of living crisis started to bite, this left many people struggling to make ends meet during treatment. We saw a significant increase in people reaching out for referrals to benefits advisors as energy bills rose ahead of winter. At our busiest time, we were often referring two or three people each week for expert benefits advice via our partnership with Maggie's Cancer Care charity, more than double our usual numbers. We saw an increase in demand for benefits referrals of 42%.

Difficult times for fundraising

The cost of living crisis has potential to significantly impact on the quality of life and mental wellbeing of members of our community, and also poses a risk to our organisation's income – as we are proud to receive over a third of our funding from community fundraising.

Our Trustees and CEO are introducing measures to monitor and mitigate this risk as we head into the new financial year. It is a particularly difficult environment for events, with regular weekend train strikes and venues facing staff shortages and financial uncertainty. Successful regular community events including Trucking for Dad and Joy Ride helped us reach our community income target this year, but both have confirmed that they will not take place next year, leaving our community fundraising team to seek new sources of income in 23/24.

The Aplastic Anaemia Trust

Trustees' Report

Achievements and performance highlights

How The AAT delivered public benefit in 2022/2023

The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.

In line with the governing document, the Memorandum and Articles of Association, our performance highlights for the last year in relation to the Charity's aims are set out below.

Delivering support

Our small and agile Support and Outreach team are swift to adapt to the evolving needs of aplastic anaemia patients in a rapidly changing world. Investment in the project management of this team has seen these abilities strengthened, as the online services we developed during lockdown are iterated and expanded into in-person support.

This year our support team and small group of dedicated volunteers:

- Delivered six webinars, connecting people affected by aplastic anaemia with global experts speaking about specific aspects of living with the condition
- Designed new support packs for children in hospitals and their siblings left at home, in collaboration with our Youth Board. These include a bespoke activity book designed to support a child's mental wellbeing.
- Developed a bespoke support service to provide expert support to the whole family, including parents, children, siblings, grandparents and wider family networks
- Launched a new online Managing Stress Course, designed by Lesley Howells, lead psychologist from Maggie's and led by psychologists to deliver expert mental health and resilience support to small groups.
- Delivered our Winter Wellness programme offering our community various support options to help them through the challenges of the winter season
- Continued to facilitate and moderate daily discussion in our active Patient Support Facebook Group.
- Transformed our regional "AAT Chats" into seven monthly online meet-ups, designed to connect patients who are at the same stage of their journey with aplastic anaemia.
- Created an online book club, to help bring our community together.
- Continued to offer one to one support via messenger, email, support line calls and WhatsApp as preferred by the individual community member.
- Our Youth Board have continued to offer their voice to ensure that the Support & Outreach team are considering the needs of young people with aplastic anaemia.

Building partnerships

Building successful partnerships is the heart of our organisational strategy, and this year has seen fantastic results from this approach. The National Lottery Community Fund approved our ambitious three-year Better Together for Healthy Bone Marrow project, with work commencing in September 2022. This work will significantly improve our organisational resilience and capacity, and that of six other smaller charities, all of which are currently volunteer-led and support communities with similar or related conditions:

- Congenital Anaemia Network (Congenital Anaemia)
- DBA UK (Diamond Blackfan Anaemia)

The Aplastic Anaemia Trust

Trustees' Report

- DC Action (Dyskeratosis Congenita)
- PNH Support (Paroxysmal Nocturnal Haemoglobinuria)
- Fanconi Hope (Fanconi Anaemia)
- SDS UK (Shwachman Diamond Syndrome)

We were delighted to deliver our first National Community Survey, in collaboration with the same partner charities. The survey was conducted in November 2022, with follow-up qualitative interviews taking place in early 2023. This was the ideal project to collaborate on with support from pharmaceutical partners, and this first stage was sponsored by Alexion, Roche, and Sobi. In total, the quantitative survey received 434 responses – a high representative sample size for these ultra rare conditions. This was followed up by further qualitative research. The results will form the backbone of our strategy and work plan for the next few years and provide a real clarity of vision. Phase two of this project will take place in 2023/24, with a joint campaign and full report published to communicate findings and recommendations.

Our partnership with Maggie's has gone from strength to strength this year. At Leeds Hospital, a key hub of expertise for aplastic anaemia, we have now established weekly face-to-face aplastic anaemia coffee mornings at the Maggie's centre there. Zoe from our team is working with Maggie's to provide joined up support that ensures people diagnosed with aplastic anaemia in Leeds have the same access to the warm, expert Maggie's support provided to cancer patients – plus the connection to other aplastic anaemia patients and rare disease understanding, direct from The AAT. We hope to scale and replicate this successful model in other areas. We were delighted to welcome Lesley Howells, Lead Psychologist from Maggie's to work with us (and the other partner charities) on the Better Together project one day a week to establish a mental wellbeing framework that will enhance and professionalise our offering to members of our community who struggle with the impact of aplastic anaemia on their mental health.

We are working with Contact, a charity for families with disabled children, to use funding from The Pears Foundation to establish a specific support programme for families affected by aplastic anaemia. We are proud to report that 49 people (including children, siblings, cousins, grandparent, carers and parents) have benefitted this year from this Family Support Project, which began in September 2022.

Research Highlights

Covid Vaccine Research Published

In December 2021, Professor Pete Hillmen and Alexandra Pike from the Leeds research team announced to our community that the research we funded revealed that aplastic anaemia and PNH patients do mount an immune response to the Covid-19 vaccine, although it is particularly important for the patients to receive a second dose. In June this year, this research was published in [The Lancet Haematology](#).

Trialling new treatment

The TIARA Trial at King's, which The Aplastic Anaemia Trust is co-funding with LifeArc, experienced delays during the pandemic, so it was fantastic news this year to see the first aplastic anaemia patients in the world receive T regulatory cells as a potential new treatment for the condition. The trial is now on track and we look forward to sharing more news next year, once more patients have received the treatment.

Funding new research

This year The Aplastic Anaemia Trust convened a new panel of patients to assess the perceived benefit of two research proposals, received as a result of our call to apply for £20k in research funding. Both proposals received high scores and glowing comments from patients, but a clear favourite among patients and on peer review was a study into Mutation timing and clonal trajectories in aplastic anaemia. This research project brings together researchers from Leeds, Cambridge and the Sangar Institute in partnership to investigate the genes of people with aplastic anaemia to take the first steps in finding ways to better predict treatment responses and later complications, such as cancer.

The Aplastic Anaemia Trust

Trustees' Report

Building a registry for children with AA

Recruitment for our paediatric UK bone marrow failure registry and biobank was completed in June. 45 children with idiopathic Severe Aplastic Anaemia have been recruited over a three year period, in a project led by Dr Sujith Samarasinghe, Great Ormond Street Hospital, London.

Peripheral blood and bone marrow has been stored on all patients, and follow up has been received. The last set of follow up is due next year in June and the final payment will be due then. The AAT are waiting on an updated invoicing schedule and report from GOSH in order to release the second instalment of funds which is overdue to be invoiced, and reserved in our accounts.

Fundraising Highlights

We relaunched our annual Super Rare campaign to allow the six other small organisations in the Better Together partnership to fundraise alongside us. Despite the challenging fundraising environment, our community stepped up - and Super Rare hit target for The Aplastic Anaemia Trust, raising £21,189 against a target of £20,000 for our charity, and a total of £32,851 across all the charity partners.

A turbulent summer for events meant key fundraisers were repeatedly impacted by train strikes, and disruption resulting from the Queen's death and mourning period. Despite these challenges, our fundraising team rose to the challenge supporting a full Great North Run team and delivering a new cycling event, Joy Ride, through Kent vineyards, which raised £18,000. 145 people took part in our flagship walking events in Windsor Great Park and the Peak District and, later in the year, we expanded our popular Santa Splash event to Edinburgh, providing a meet up point for people we had been supporting in Scotland throughout the year. In total, 110 people got in the chilly sea at a Santa Splash event this year.

We thank the National Lottery, the Pears Foundation and Contact, and the Meikle Foundation for their funding and support this year.

Risk management

The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT's charitable activities.

A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.

The Aplastic Anaemia Trust

Trustees' Report

Going Concern

The Trustees consider there are no material uncertainties about the charitable company's ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.

Financial Review

How our income and expenditure changed in 2022/23

Unrestricted income for the year totalled £193,950 (21/22: £223,218) and expenditure amounted to £307,484 (21/22: £132,267) resulting in net expenditure on unrestricted funds for the year of £113,534 (21/22 net income : £90,951). Restricted income of £280,350 was received in the year. Expenditure incurred and charged against restricted income funds amounted to £173,921 (21/22: £108,068), leaving balances on restricted funds totalling £110,000 at 31 March 2023.

Managing our income across a range of rare bone marrow failures

Two large, complex partnership projects this year brought new challenges (and great rewards). It is useful to note with these accounts that the grant income from The National Lottery Community Fund, and the Survey Sponsorship income from pharmaceutical partners both represent budgets which are managed by The Aplastic Anaemia Trust to deliver work that is designed to benefit our Better Together partnership of seven small organisations (as above), and the communities of people that all seven organisations represent. Both projects fall within The Aplastic Anaemia Trust's charitable objectives of supporting people suffering from bone marrow disease and immune defects, and by working collaboratively with partnership organisations who are expert in their specific conditions, we are able to replicate benefits and learning across all of our organisations and speak with one voice.

Our reserves position and policy update

Over the last two years, in response to significantly increased community need during the pandemic, and thanks to the expert management of CEO Stevie Tyler, The Aplastic Anaemia Trust has significantly expanded our team and activities. This has been possible thanks to generous support and emergency funding made available during the pandemic.

The challenge we now face is how to be sure of sustainable funding for these essential support services, while also being able to invest in research.

In response, this year we have updated our reserves policy to ensure we hold 9 months core operating costs in unrestricted reserves, to ensure that the charity will be able to maintain vital services and re-establish our income, should one source of income drop unexpectedly. Our reasoning, method of calculating required funds, and the purpose for retaining these reserves is outlined in our updated reserves policy.

This nine months of core operating costs will be recalculated annually. In November 2022 we calculated that the target figure should be £196k. As of 31 March 2023, our unrestricted reserves stand at £330k.

Our budgeted plans for the year 23/24 are projected to spend down our reserves to the target level by the end of the next financial year. This budget does not include investment in new research projects. Our priority for the next financial year is to seek funding to cover the costs of work delivered by our support team, which will provide confidence that our current level of support is sustainable and enable us to invest future income raised by community fundraising in research partnership projects.

The Aplastic Anaemia Trust

Trustees' Report

Pharmaceutical Industry income in 22/23

After relaxing the policy requirement during the pandemic, when community fundraising income was severely restricted, the trustees have reinstated our policy to strive to keep pharmaceutical funding levels under a third of our total income, which has been achieved this year.

As the total figure of allowed pharmaceutical fundraising is higher as a result of income from the National Lottery Better Together grant (a project to benefit six other charity partners) it was fitting to use this opportunity to fund a project that also benefits all seven communities, so we were very pleased to receive support from Sobi, Roche and Alexion to fund the National Community Survey.

Sobi also provided grant funding for our Winter Wellness programme this year, enabling us to deliver extra support to our communities over winter, a time when the isolation and anxiety experienced by many of our community are exacerbated by heightened worries about seasonal infections among those who are immunocompromised, and missing out on seasonal festivities.

Structure, Governance and Management

Expanding our Board

In the previous financial year, The AAT updated our governance structure to create our Research and Clinical Advisory Panel, and conducted a skills audit of our Board of Trustees. By advertising and reaching out via personal networks, 2022-2023 saw five new appointments to our board.

New Trustees were interviewed by the Chair and CEO, attended a Board meeting as Guests and on appointment were provided with a pack of information including, inter alia, a copy of the most recent annual report and financial statements, a copy of the charitable company's Memorandum and Articles of Association and minutes of recent Trustee meetings. New Trustees formally accept the invitation to join the Board and were approved at a Board Meeting before being eligible to vote. The Trustees are also Members of the charitable company.

Our new board members bring significant professional charity experience and financial knowledge, skills that were identified as desirable in our skills audit. We also hoped to recruit new Board Members who have personal experience of the condition from a different perspective. As Chair of our Youth Board, Callum Tempest had been contributing significantly to the running of our organisation and ensuring the voices of young people affected by aplastic anaemia are heard at every level, so we were delighted when he decided to take the next step and join the board.

We also bid goodbye to two very long-serving trustees, - Sven Moos and Paul Cossell, both of whom remain in non-executive Ambassador roles, to provide insight and advice when called on. We are so grateful to Sven and Paul for their longinspiring years of service to the charity, steering us through difficult times and leaving us in good shape to meet the challenges ahead.

Chief Executive

Our Chief Executive, Stevie Tyler, went on Maternity Leave in November 2022. Our Head of Comms and Fundraising, Ellie Dawes, has been stepping up as Acting CEO while Stevie is away, with Stevie planning a phased return from October 2023.

The Trustees have delegated day-to-day management of the Trust's affairs to Stevie Tyler and Ellie Dawes during this financial period.

The Aplastic Anaemia Trust

Trustees' Report

Research and Clinical Advisory Panel and Youth Board

We also bid goodbye to Professor Pete Hillmen from our Research and Clinical Advisory Panel, who stepped down as Vice-Chair due to his appointment to a new role within the pharmaceutical industry, which the RCAP agreed could represent a conflict of interest. We are deeply indebted to Pete for his fantastic contributions to further the interests of our patient community over the years through research and his clinical career.

There were also changes on our Youth Board. Harry Branthwaite, Ben Stephenson, Elin Davies, Alex Reid and Lily Pope left the board early this year, many having simply reached too great an age (i.e. over 25 years old) to sit on the panel. We were pleased to welcome a new member, Harry Clague, bringing Youth Board membership up to a total of six at the end of the year, with a new recruitment drive launching soon. We thank all Youth Board Members, retired and current, for their insight and ideas which have been extremely valuable.


The RCAP members are:

- Dr Dominic Culligan
- Professor Josu de la Fuente
- Dr Morag Griffin
- Dr Austin Kulasekararaj
- Professor Ghulam Mufti (Chair)
- Dr Bethany Mitchell
- Dr Sujith Samarasinghe
- Professor John Snowden
- Professor Rod Skinner
- Dr Sanjay Tewari
- Professor Alan Warren
- Dr Keith Wilson

Small companies provision statement

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The annual report was approved by the trustees of the charity on 31 August 2023 and signed on their behalf by:



.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2023 which are set out on pages 13 to 21.

Respective responsibilities of trustees and examiner

As the company's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and eligible for independent examination, I report in respect of my examination of the company's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since The Aplastic Anaemia Trust's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of , which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust



.....
Mark Heaton FCCA FCIE DChA
KM
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

31 August 2023

The Aplastic Anaemia Trust

Statement of Financial Activities for the Year Ended 31 March 2023 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2023 £	Unrestricted funds £	Restricted funds £	Total 2022 £
Income from:							
Donations and legacies	3	147,763	70,000	217,763	185,533	-	185,533
Grants receivable	4	-	210,350	210,350	10,000	9,971	19,971
Fund-raising events	5	43,450	-	43,450	27,661	-	27,661
Investment income	6	2,737	-	2,737	24	-	24
Total income		<u>193,950</u>	<u>280,350</u>	<u>474,300</u>	<u>223,218</u>	<u>9,971</u>	<u>233,189</u>
Expenditure on:							
Raising funds	7	(26,047)	-	(26,047)	(23,345)	-	(23,345)
Charitable activities	8	(281,437)	(173,921)	(455,358)	(108,923)	(108,068)	(216,991)
Total expenditure		<u>(307,484)</u>	<u>(173,921)</u>	<u>(481,405)</u>	<u>(132,268)</u>	<u>(108,068)</u>	<u>(240,336)</u>
Net (expenditure)/income		<u>(113,534)</u>	<u>106,429</u>	<u>(7,105)</u>	<u>90,950</u>	<u>(98,097)</u>	<u>(7,147)</u>
Net movement in funds		(113,534)	106,429	(7,105)	90,950	(98,097)	(7,147)
Reconciliation of funds							
Total funds brought forward		<u>443,652</u>	<u>3,571</u>	<u>447,223</u>	<u>352,702</u>	<u>101,668</u>	<u>454,370</u>
Total funds carried forward	18	<u>330,118</u>	<u>110,000</u>	<u>440,118</u>	<u>443,652</u>	<u>3,571</u>	<u>447,223</u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2022 is shown in note 18.

The Aplastic Anaemia Trust
(Registration number: 05174065)
Balance Sheet as at 31 March 2023

	Note	2023 £	2022 £
Current assets			
Debtors	14	19,122	131
Cash at bank and in hand		<u>614,950</u>	<u>607,334</u>
		634,072	607,465
Creditors: Amounts falling due within one year	15	<u>(145,709)</u>	<u>(77,536)</u>
Total assets less current liabilities		488,363	529,929
Creditors: Amounts falling due after more than one year	16	<u>(48,245)</u>	<u>(82,706)</u>
Net assets		<u>440,118</u>	<u>447,223</u>
Funds of the charity:			
Restricted income funds			
Restricted funds		110,000	3,571
Unrestricted income funds			
Unrestricted funds		<u>330,118</u>	<u>443,652</u>
Total funds	18	<u>440,118</u>	<u>447,223</u>

For the financial year ending 31 March 2023 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476. However, in accordance with section 44 of the Charities and Trustee Investment (Scotland) Act 2005, the accounts have been examined by an independent examiner whose report appears on page 12; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 13 to 21 were approved by the trustees, and authorised for issue on 31 August 2023 and signed on their behalf by:

.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.

The address of its registered office is:

1st Floor, Block C

The Wharf

Manchester Road

Burnley

Lancashire

BB11 1JG

These financial statements were authorised for issue by the trustees on 31 August 2023.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.

Basis of preparation

The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity is exempt from preparing a cash flow statement.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Income from donations

	Unrestricted funds			
	General £	Restricted funds £	Total 2023 £	Total 2022 £
Donations and legacies	147,763	70,000	217,763	185,533
	<u>147,763</u>	<u>70,000</u>	<u>217,763</u>	<u>185,533</u>

4 Income from charitable activities

	Restricted funds £	Total 2023 £	Total 2022 £
Grants receivable	210,350	210,350	19,971
	<u>210,350</u>	<u>210,350</u>	<u>19,971</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

5 Income from fund-raising

	Unrestricted funds	Total 2023	Total 2022
	General £	£	£
Fund-raising events	43,450	43,450	27,661
	<u>43,450</u>	<u>43,450</u>	<u>27,661</u>

6 Investment income

	Unrestricted funds	Total 2023	Total 2022
	General £	£	£
Interest receivable and similar income; Interest receivable on bank deposits	2,737	2,737	24
	<u>2,737</u>	<u>2,737</u>	<u>24</u>

7 Expenditure on raising funds

	Unrestricted funds	Total 2023	Total 2022
	General £	£	£
Fundraising staff costs	26,047	26,047	23,345
	<u>26,047</u>	<u>26,047</u>	<u>23,345</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

8 Expenditure on charitable activities

	Note	Unrestricted funds		Total 2023 £	Total 2022 £
		General £	Restricted funds £		
Patient Information, outreach & support		223,741	173,921	397,662	277,860
Research & grants		55,946	-	55,946	(63,576)
Governance costs	9	1,750	-	1,750	2,707
		<u>281,437</u>	<u>173,921</u>	<u>455,358</u>	<u>216,991</u>

9 Analysis of governance and support costs

Governance costs

	Unrestricted funds		Total 2023 £	Total 2022 £
	General £			
Independent Examiner's remuneration	1,750		1,750	2,707
	<u>1,750</u>		<u>1,750</u>	<u>2,707</u>

10 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

11 Staff costs

The aggregate payroll costs were as follows:

	2023 £	2022 £
Staff costs during the year were:		
Wages and salaries	207,524	165,430
Social security costs	19,037	9,642
Pension costs	4,816	3,524
	231,377	178,596

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2023 No	2022 No
Charitable activities	9	6

The number of employees whose emoluments fell within the following bands was:

	2023 No	2022 No
£60,001 - £70,000	1	1

12 Independent examiner's remuneration

	2023 £	2022 £
Examination of the financial statements	1,750	2,707

13 Taxation

The charity is a registered charity and is therefore exempt from taxation.

14 Debtors

	2023 £	2022 £
Accrued income	19,122	-
Other debtors	-	131
	19,122	131

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

15 Creditors: amounts falling due within one year

	2023 £	2022 £
Research grant commitments	135,198	68,096
Accruals	10,511	9,440
	145,709	77,536

16 Creditors: amounts falling due after one year

	2023 £	2022 £
Research grant commitments	48,245	82,706

17 Pension and other schemes

Defined contribution pension scheme

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £4,816 (2022 - £3,524).

Contributions totalling £Nil (2022 - £Nil) were payable to the scheme at the end of the year and are included in creditors.

18 Funds

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Unrestricted funds				
General	443,652	193,950	(307,484)	330,118
	443,652	193,950	(307,484)	330,118
Restricted funds				
National Lottery - Better Together	-	191,906	(86,232)	105,674
Contact a Family	-	8,500	(4,174)	4,326
Awards For All	3,571	-	(3,571)	-
Winter Wellness Project	-	19,944	(19,944)	-
National Community Survey	-	60,000	(60,000)	-
	3,571	280,350	(173,921)	110,000
Total funds	447,223	474,300	(481,405)	440,118

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2023

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Unrestricted funds				
General	352,702	223,218	(132,268)	443,652
	<u>352,702</u>	<u>223,218</u>	<u>(132,268)</u>	<u>443,652</u>
Restricted funds				
Marrowkidz Fund	101,668	-	(101,668)	-
Awards For All	-	9,971	(6,400)	3,571
	<u>101,668</u>	<u>9,971</u>	<u>(108,068)</u>	<u>3,571</u>
Total funds	<u><u>454,370</u></u>	<u><u>233,189</u></u>	<u><u>(240,336)</u></u>	<u><u>447,223</u></u>

19 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	2023 Total funds
	General £	£	£
Current assets	524,073	110,000	634,073
Current liabilities	(145,709)	-	(145,709)
Creditors over 1 year	(48,245)	-	(48,245)
Total net assets	<u>330,119</u>	<u>110,000</u>	<u>440,119</u>
	Unrestricted funds	Restricted funds	2022 Total funds
	General £	£	£
Current assets	603,894	3,571	607,465
Current liabilities	(77,536)	-	(77,536)
Creditors over 1 year	(82,706)	-	(82,706)
Total net assets	<u>443,652</u>	<u>3,571</u>	<u>447,223</u>

THE APLASTIC ANAEMIA TRUST

England & Wales - Charity number 1107539

Accounts

Company registration number: 05174065

Charity registration number: 1107539

Charity number (Scotland): SC049810

The Aplastic Anaemia Trust

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2022

KM
Chartered Accountants
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

The Aplastic Anaemia Trust

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 18

The Aplastic Anaemia Trust

Reference and Administrative Details

Chair	A Conquy
Trustees	A Conquy P M Cossell J L Cozens S Moos T Stephenson
Secretary	S L Tyler
Principal Office	1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
Company Registration Number	05174065
Charity Registration Number	1107539
Charity Registration Number Scotland	SC049810
Bankers	CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 5JQ
Independent Examiner	KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG

The Aplastic Anaemia Trust

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2022.

Trustees

A Conquy

P M Cossell

J L Cozens

Prof P H Hillmen (resigned 3 February 2022)

Prof J C W Marsh (resigned 3 February 2022)

S Moos

Prof G M Mufti (resigned 3 February 2022)

Dr S R Samarasinghe (resigned 3 February 2022)

T Stephenson

Introduction

As reported last year, 2020-2021 saw the range and depth of our community work fundraising and communications grow and 2021- 2022 has been a very significant year of consolidation of that work.

The Aplastic Anaemia Trust (AAT) is fortunate to have such a dynamic and professional team, headed by our CEO, Stevie Tyler. Their work around developing the detail of our strategy, combined with broadening our relationships, alliances and strategic partnerships has meant that the charity achieves positive impacts, exceeding expectations for a charity of our size and we are proud we can serve our community in an increasingly impactful way. It has been a particularly strong year for fundraising, with events and community fundraising bouncing back and a strong focus on stewardship.

Although Covid has been always in the frame impacting the health of patients with aplastic anaemia as well as our own team, we have been able continue to grow our reach by keeping our support and outreach largely online. Throughout, our clear focus has been on developing our relationships with our community, ensuring we meet their needs and retain their loyalty and good will through strong supporter experience and increasingly thorough data collection.

Another focus has been governance. We began the process of reconfiguring and strengthening our Board, informed by a skills audit, alongside the development of a new Research and Clinical Advisory panel comprising 11 leading clinicians and researchers working in the field of aplastic anaemia whose guidance will be every more invaluable to the staff and the board regarding our investments in research as well as the needs of people with aplastic anaemia and their families. The charity is indebted to them for their knowledge and experience as well their generous support and advice.

Thank you to everyone in our community, and to our supporters, volunteers, and donors for their incredible efforts in fundraising and growing the awareness of aplastic anaemia. And equal thanks to the Aplastic Anaemia Trust's staff and to Stevie Tyler for their dedication, imagination and skilful persistence, as well as their expertise. Finally, our thanks to the trustees on the board for their support.

We hope that you will see in the following pages of our Annual Report the extent to which our pledge to continue to help fight aplastic anaemia and help those who live with it is stronger than ever.

The Aplastic Anaemia Trust

Trustees' Report

What is Aplastic Anaemia?

Aplastic anaemia (AA) is a rare and life-threatening form of bone marrow failure. Most cases are acquired. However inherited types of AA are also quite common and can present in adults, not just in children.

The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every aplastic anaemia sufferer and their loved ones and to help relieve the immense disease burden.

Our Mission, Vision and Objectives

The objects of the charity as defined in its Articles of Association are to relieve the sickness of those people suffering from bone marrow disease and immune defects.

Vision

Everyone affected by aplastic anaemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.

Mission

We deliver our vision through two key strategies:

- Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
- Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.

Our strategic objectives

- A. Ensure everyone affected by AA has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.
- B. Improve the knowledge and understanding of AA through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.
- C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes.
- D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.

Our fundraising acts as an enabler in our strategy, ensuring we have the resources to deliver these objectives.

The challenges we worked hard to address in 2021/22

- Delivering a whole calendar of in-person fundraising and community events for the first time with the CEO and fundraising team in place
- Developing a robust income and expenditure plan for the next three years, ensuring a sustainable organisation.

AAT's achievements and performance highlights for public benefit in 2021/2022

The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.

In line with the governing document, the Memorandum and Articles of Association, our performance highlights for the last year in relation to the Charity's aims are set out below.

The Aplastic Anaemia Trust

Trustees' Report

1. Adult patient information, outreach and support

COVID Ongoing

The continuing COVID-19 pandemic has been a significant concern for our community this year, with many community members experiencing issues accessing booster vaccinations, monoclonal antibody and antiviral treatments, and more significantly, feeling unsure what to do to keep themselves safe at points during the year where wider restrictions, and support mechanisms for people who are clinically extremely vulnerable were relaxed, or withdrawn completely.

To ensure that our community were able to access reliable, accurate and relevant information about matters concerning COVID-19, we continually revised our website with the latest updates relating to vaccinations, changes to shielding guidelines and access to treatments. In cases where our community reported issues, such as with accessing booster vaccinations, or treatments in cases where they tested positive for COVID-19, we advocated for our community, developing resources for them to advocate their need for vaccinations or treatment, and fed back their concerns to the Department for Health through our partners, including the Specialised Health Care Alliance and the Blood Cancer UK Vaccine Taskforce.

Throughout the year, we saw an ever-increasing demand for support across all channels, including our Helpline, private Facebook group and website. COVID-19-related enquiries accounted for more than twenty per-cent of all of the issues that we supported members of our community with.

Newly diagnosed patients

We also observed a significant increase in the number of newly diagnosed people approaching us for support this year. Almost 20% of all enquiries to our support service were from people, or the families of people, who were newly diagnosed with aplastic anaemia. We believe that this may be reflective of wider pressures in the NHS, such as people experiencing delays in receiving a formal diagnosis, or accessing specialist support.

Winter Isolation

Over the winter months of 2020, many of our community members reported that they felt isolated during the times that the UK was in lockdown, which had a detrimental impact on their mental wellbeing. Keen to prepare for this, we developed a programme of online wellbeing events, taking place between October and March, to develop cohesion amongst our community who may have been isolating, and equip them with practical skills and techniques to maintain their wellbeing. We facilitated a wide range of events, ranging from meditation to expert-led webinars exploring themes such as 'managing uncertainty' and 'managing fatigue', all key issues which can be a significant burden for people affected by aplastic anaemia.

2. Paediatric patient information, outreach support

Our key focus in paediatric work this year has been the creation and development of The Aplastic Anaemia Trust Youth Board.

The six-month Youth Board Pilot saw 10 young people affected by aplastic anaemia take a new role in learning about and advising on the way our charity operates.

Some notable successes of the Youth Board during our six-month pilot were:

The Aplastic Anaemia Trust

Trustees' Report

- Creating a Tough Mudder fundraising team
- Instigating a rehabilitation project for young people in treatment for AA - The AAT is now in talks with CAN Rehab about launching a pilot project
- The AA Voices Film Project, which is running in partnership with Fully Focussed to empower four young people affected by AA to tell their stories through film
- Members providing valuable feedback on the MarrowKidz project and others, to report back to funders and inform the next phase of our work for young people
- Contacts at The National Lottery Community Fund commented on how impressed they are by the Youth Board, and how its existence could make The AAT more likely to receive support in the future
- The Youth Board advised the Support and Outreach team to send cards and gifts to children with AA in isolation at Christmas, because this is an especially hard time for children and young people.
- Youth Board Members provided important services for the charity through volunteering opportunities, including making befriending phone calls and producing a new resource about AA for Maggie's centre heads.
- Members have widened their understanding of how the charity is run - from the finances and funding to supporting people
- Bringing members together for peer support was a key benefit of the Youth Board. Elin said "*Knowing the meetings are coming up, it was nice to speak to people who know what we're going through. You don't have to explain yourself, everyone just knows.*"

Following the successful Pilot, the Youth Board was evaluated to relaunch in April 2023, with a new round of recruitment and ambitious plans to engage a wider group of young people and strengthen the Youth Board's relationship with the Board of Trustees.

3. Research

The AAT is currently committed to funding three important research projects, to progress treatments of aplastic anaemia and to further the understanding of the disease.

a. Identification and relevance of novel somatic mutations in patients with aplastic anaemia, led by Dr Alex Smith and Professor Ghulam Mufti, King's College Hospital, London

In summary:

Clonal evolution, in recovering bone marrow, following immunosuppressive treatment in AA has important clinical and prognostic implications.

Update:

Since our seminal paper in the journal *Blood*, others have reported similar outcomes - and is now an active area of interest and research being prospectively carried out by various centres. We continue with long term follow-up of patients enrolled in the EBMT sponsored RACE study, to determine emergence and patterns of mutation (co-exist, symbiotic or attritional) and its correlation with disease relapse and evolution. We have now further refined our next generation sequencing (NGS) to detect these mutations to 44 genes (commonly associated with myeloid disorders).

In addition, our CHIP study (Clonal haematopoiesis of indeterminate potential) serves as a useful comparator group.

We continue to receive samples and monitor patients in this study and will look forward to presenting results/publications in due course.

The Aplastic Anaemia Trust

Trustees' Report

b. Establishment of a paediatric UK bone marrow failure registry and biobank, led by Dr Sujith Samarasinghe, Great Ormond Street Hospital, London

This project is moving into its final year, after which we anticipate the publication of a research paper sharing the results of this project.

GOSH and the AAT are working together to create a funding proposal to expand the registry over a ten-year period.

c. Production of expanded autologous regulatory T cells to treat patients with refractory aplastic anaemia in a phase I dose study, led by Professor Ghulam Mufti, King's College Hospital, London

Progress headlines:

After delays due to covid and Brexit, recruitment for this trial begins in Summer 2022.

4. Fundraising

2021/22 was a very strong fundraising year for us, raising in excess of £210,000 against a predicted £165,000. This was due to a strong community and events calendar and excellent stewardship of our supporters. The third year of our annual campaign Super Rare, culminating in Aplastic Anaemia Awareness Day, also helped give focus to our fundraising. In addition, our Pharma relationships enabled us to deliver our Winter Wellbeing programme and raised £60,000 towards our target to support it.

5. Awareness and strategic capacity

The primary goals of our awareness-raising in 2021/22 were to bring a sense of community and joy to people who were still feeling isolated and unsure about socialising two years into a pandemic.

Our new Sunshine magazine, available online and in print, brought good news to our community during the winter season, with 3 editions communicating messages around vaccine efficacy, wellbeing advice and positive stories about research.

An incredible 87 people joined us for a walk on the day after Aplastic Anaemia Awareness Day, some remotely on our Together Walk and others in person in the Peak District, a great sign that the campaign we designed to connect people remotely during lockdown has potential to grow further with in-person events.

This year during the Super Rare campaign, we took advantage of a special opportunity offered to charities to run a digital ad campaign across various UK news websites including The Guardian, to tell the general public about our work to fund Covid-19 vaccine research for people with rare bone marrow failure. Our advert achieved 1.9million impressions and was clicked by 918 people.

Looking ahead

The AAT will continue to build on the core activities outlined in the annual report, for the benefit of its patient and family communities.

2023 will be an important year for our Support and Outreach team, who will begin to develop a programme of thematic services based on unmet needs in the community.

It will be significant for the development of our evidence base, through the design and delivery of the first ever national community survey for people with AA and related rare bone marrow failures.

The Aplastic Anaemia Trust

Trustees' Report

The principles underpinning the AAT's strategic objectives will be community-first ethos, collaborative working and organisational excellence.

Risk management

The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT's charitable activities.

A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.

Going Concern

The Trustees consider there are no material uncertainties about the charitable company's ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.

Financial Review

Unrestricted income for the year totalled £223,218 (2021: £222,766) and expenditure amounted to £132,267 (2021: £151,461) resulting in net income on unrestricted funds for the year of £90,951 (2021: £71,305). Expenditure has been reduced by £63,576 of research grant commitments overprovided from before the pandemic and no longer needed. In addition, restricted income of £9,971 was received in the year. Expenditure incurred and charged against restricted income funds amounted to £108,068 (2021: £123,474), leaving balances on restricted funds totalling £3,571 at 31 March 2022.

At the end of the year the charity had free, unrestricted reserves of £443,653.

Reserves Policy

The Trustees have considered the charitable company's position with regard to formulating a reserves policy, aligned with the organisation's strategy moving forward.

Under its reserve policy the charitable company follows the following principles:

Ensure that it has an operating income reserve equivalent to approximately 12 months of operational costs of the charity plus a reasonable amount of investment funds to draw upon, in line with the strategy, to the minimum value of £200,000, approved by the trustees in the Reserves Policy in March 2022.

Ensure that the charitable company retains reasonable reserves to cover unforeseen emergency or other unexpected need for funds.

Given the above, the Trustees have allocated funds to a series of projects in 2023 which support the organisational strategy:

- New clinical research projects
- Impact evaluation
- S&O team resource

The Aplastic Anaemia Trust

Trustees' Report

Recruitment & appointment of Trustees

When recruiting new Trustees, the Trust looks for individuals with skills and experience which are considered of value to the charity and which are not necessarily held by existing Trustees. Potential Trustees are interviewed by existing Trustees and, if appointed, are provided with a pack of information including, inter alia, a copy of the most recent annual report and financial statements, a copy of the charitable company's Memorandum and Articles of Association and minutes of recent Trustee meetings. New Trustees then sign a declaration of willingness to act as a charity Trustee before being eligible to vote.

The Trustees are also Members of the charitable company.

Chief Executive

The Trustees have delegated day-to-day management of the Trust's affairs to Stevie Tyler, the AAT's Chief Executive, during this financial period.

Research and Clinical Advisory Panel Members

The RCAP members were confirmed in post in December 2021. They are not trustees but an advisory panel of experts reporting to the Board.

Chair - Prof. Ghulam Mufti
Vice-Chair - Prof. Peter Hillmen
Dr. Sujith Samarasinghe
Dr. Dominic Culligan
Dr. Josu de la Fuente
Dr Austin Kulasekararaj
Dr. Bethany Mitchell
Prof. Rod Skinner
Prof. John Snowden
Dr. Sanjay Tewari
Prof. Alan Warren
Dr. Keith Wilson

Small companies provision statement

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The annual report was approved by the trustees of the charity on 31 August 2022 and signed on their behalf by:

.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2022 which are set out on pages 10 to 18.

Respective responsibilities of trustees and examiner

As the company's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and eligible for independent examination, I report in respect of my examination of the company's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

.....
Mark Heaton FCCA FCIE DChA
KM
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

31 August 2022

The Aplastic Anaemia Trust

Statement of Financial Activities for the Year Ended 31 March 2022 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2022 £	Unrestricted funds £	Restricted funds £	Total 2021 £
Income from:							
Donations and legacies	3	185,533	-	185,533	113,987	-	113,987
Grants receivable		10,000	9,971	19,971	102,966	-	102,966
Fund-raising events		27,661	-	27,661	1,091	-	1,091
Other income		-	-	-	4,722	-	4,722
Investment income	5	24	-	24	-	-	-
Total income		<u>223,218</u>	<u>9,971</u>	<u>233,189</u>	<u>222,766</u>	<u>-</u>	<u>222,766</u>
Expenditure on:							
Raising funds	6	(23,345)	-	(23,345)	(3,186)	(21,851)	(25,037)
Charitable activities	7	(108,922)	(108,068)	(216,990)	(148,275)	(101,623)	(249,898)
Total expenditure		<u>(132,267)</u>	<u>(108,068)</u>	<u>(240,335)</u>	<u>(151,461)</u>	<u>(123,474)</u>	<u>(274,935)</u>
Net income/(expenditure)		<u>90,951</u>	<u>(98,097)</u>	<u>(7,146)</u>	<u>71,305</u>	<u>(123,474)</u>	<u>(52,169)</u>
Net movement in funds		90,951	(98,097)	(7,146)	71,305	(123,474)	(52,169)
Reconciliation of funds							
Total funds brought forward		<u>352,702</u>	<u>101,668</u>	<u>454,370</u>	<u>281,397</u>	<u>225,142</u>	<u>506,539</u>
Total funds carried forward	17	<u>443,653</u>	<u>3,571</u>	<u>447,224</u>	<u>352,702</u>	<u>101,668</u>	<u>454,370</u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2021 is shown in note 17.

The Aplastic Anaemia Trust
(Registration number: 05174065)
Balance Sheet as at 31 March 2022

	Note	2022 £	2021 £
Current assets			
Debtors	13	131	-
Cash at bank and in hand		<u>607,334</u>	<u>697,621</u>
		607,465	697,621
Creditors: Amounts falling due within one year	14	<u>(77,535)</u>	<u>(243,251)</u>
Total assets less current liabilities		529,930	454,370
Creditors: Amounts falling due after more than one year	15	<u>(82,706)</u>	-
Net assets		<u><u>447,224</u></u>	<u><u>454,370</u></u>
Funds of the charity:			
Restricted income funds			
Restricted funds		3,571	101,668
Unrestricted income funds			
Unrestricted funds		<u>443,653</u>	<u>352,702</u>
Total funds	17	<u><u>447,224</u></u>	<u><u>454,370</u></u>

For the financial year ending 31 March 2022 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476. However, in accordance with section 44 of the Charities and Trustee Investment (Scotland) Act 2005, the accounts have been examined by an independent examiner whose report appears on page 12; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 10 to 18 were approved by the trustees, and authorised for issue on 31 August 2022 and signed on their behalf by:

.....
A Conquy
Trustee

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.

The address of its registered office is:

1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

These financial statements were authorised for issue by the trustees on 31 August 2022.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.

Basis of preparation

The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity is exempt from preparing a cash flow statement.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Income from donations

	Total 2022 £	Total 2021 £
Donations and legacies	185,533	113,987
	<u>185,533</u>	<u>113,987</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

4 Income from charitable activities

	Restricted funds	Total 2022	Total 2021
	£	£	£
Grants receivable	9,971	19,971	102,966
	9,971	19,971	102,966
	9,971	19,971	102,966

5 Investment income

	Unrestricted funds		Total 2021
	General	£	£
Interest receivable and similar income; Interest receivable on bank deposits		24	24
		24	24
		24	24

6 Expenditure on raising funds

	Unrestricted funds		Total 2021
	General	Total 2022	£
	£	£	£
Raising funds	23,345	23,345	25,037
	23,345	23,345	25,037
	23,345	23,345	25,037

7 Expenditure on charitable activities

		Unrestricted funds	Restricted funds	Total 2022	Total 2021
	Note	General	£	£	£
		£	£	£	£
Patient Information, outreach & support		169,791	108,068	277,859	184,501
Research & grants		(63,576)	-	(63,576)	63,453
Governance costs	8	2,707	-	2,707	1,944
		108,922	108,068	216,990	249,898
		108,922	108,068	216,990	249,898

Expenditure has been reduced by £63,576 relating to overstated research grant commitments made prior to the pandemic.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

8 Analysis of governance and support costs

Governance costs

	Unrestricted funds	Total 2022	Total 2021
	General £	£	£
Independent Examiner's remuneration	2,707	2,707	1,400
Other governance costs	-	-	544
	<u>2,707</u>	<u>2,707</u>	<u>1,944</u>

9 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

10 Staff costs

The aggregate payroll costs were as follows:

	2022	2021
	£	£
Staff costs during the year were:		
Wages and salaries	101,668	71,961
Social security costs	9,642	5,681
Pension costs	3,524	9,360
	<u>114,834</u>	<u>87,002</u>

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2022	2021
	No	No
Charitable activities	<u>6</u>	<u>5</u>

The number of employees whose emoluments fell within the following bands was:

	2022	2021
	No	No
£60,001 - £70,000	<u>1</u>	<u>1</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

11 Independent examiner's remuneration

	2022 £	2021 £
Examination of the financial statements	<u>2,707</u>	<u>1,400</u>

12 Taxation

The charity is a registered charity and is therefore exempt from taxation.

13 Debtors

	2022 £	2021 £
Other debtors	<u>131</u>	<u>-</u>

14 Creditors: amounts falling due within one year

	2022 £	2021 £
Other taxation and social security	-	4,194
Research grant commitments	68,095	238,792
Pension scheme creditor	-	265
Accruals	<u>9,440</u>	<u>-</u>
	<u>77,535</u>	<u>243,251</u>

15 Creditors: amounts falling due after one year

	2022 £	2021 £
Research grant commitments	<u>82,706</u>	<u>-</u>

16 Pension and other schemes

Defined contribution pension scheme

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £3,524 (2021 - £9,360).

Contributions totalling £Nil (2021 - £265) were payable to the scheme at the end of the year and are included in creditors.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

17 Funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Unrestricted funds				
General	352,702	223,218	(132,267)	443,653
	352,702	223,218	(132,267)	443,653
Restricted funds				
Marrowkidz Fund	101,668	-	(101,668)	-
Awards For All	-	9,971	(6,400)	3,571
	101,668	9,971	(108,068)	3,571
Total funds	454,370	233,189	(240,335)	447,224
	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted funds				
General	281,397	222,766	(151,461)	352,702
	281,397	222,766	(151,461)	352,702
Restricted funds				
Marrowkidz Fund	158,621	-	(56,953)	101,668
Patient Information, Outreach & Support Programme Fund	34,386	-	(34,386)	-
Emergency Response Covid-19 Fund	32,135	-	(32,135)	-
	225,142	-	(123,474)	101,668
Total funds	506,539	222,766	(274,935)	454,370

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2022

18 Analysis of net assets between funds

	Unrestricted funds		2022 Total funds £
	General £	Restricted funds £	
	Current assets	603,894	
Current liabilities	(77,535)	-	(77,535)
Creditors over 1 year	(82,706)	-	(82,706)
Total net assets	443,653	3,571	447,224

	Unrestricted funds		2021 Total funds £
	General £	Restricted funds £	
	Current assets	595,953	
Current liabilities	(243,251)	-	(243,251)
Total net assets	352,702	101,668	454,370

THE APLASTIC ANAEMIA TRUST

England & Wales - Charity number 1107539

Accounts

Company registration number: 5174065

Charity registration number: 1107539

Charity number (Scotland): SC049810

The Aplastic Anaemia Trust

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2021

KM
Chartered Accountants
1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

The Aplastic Anaemia Trust

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 11
Independent Examiner's Report	12
Statement of Financial Activities	13
Balance Sheet	14
Notes to the Financial Statements	15 to 21

The Aplastic Anaemia Trust

Reference and Administrative Details

Chair	A Conquy
Trustees	A Conquy P M Cossell J L Cozens Prof P H Hillmen Prof J C W Marsh S Moos Prof G M Mufti Dr S R Samarasinghe T Stephenson
Secretary	S L Tyler
Principal Office	1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG
Company Registration Number	5174065
Charity Registration Number	1107539
Charity Registration Number Scotland	SC049810
Bankers	CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 5JQ
Independent Examiner	KM Chartered Accountants 1st Floor, Block C The Wharf Manchester Road Burnley Lancashire BB11 1JG

The Aplastic Anaemia Trust

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2021.

Trustees

A Conquy (appointed 29 April 2020)

P M Cossell

J L Cozens

Prof P H Hillmen

Prof J C W Marsh

S Moos

Prof G M Mufti

Dr S R Samarasinghe

T Stephenson (appointed 29 April 2020)

Chair's Statement

2020 - 2021 has been a momentous year for the world and against the backdrop of the pandemic the Aplastic Anaemia Trust has grown and deepened the breadth of its work in service of our community which, in its own way, has been momentous too. In the last financial year we have appointed a new CEO and seen the team grow with new roles in patient support and outreach, fundraising and communications. I salute all the staff, and particularly our CEO, Stevie Tyler, for the dynamism, professionalism and dedication they bring to their roles.

Despite Covid continuing to impact all our work, we have continued to deliver support to our communities all over the UK through our website and our increasingly engaged online community. We used this time to pilot new ways of supporting people with the emotional and psychological challenges facing those who have been shielding for 18 months.

Our clear focus has been on collaboration. We've established a strong relationship with Maggie's, the national charity whose beautiful drop-in centres across the United Kingdom, have been providing a caring environment that provide support, information and practical advice for people being treated for cancer, and now include people with Aplastic Anaemia, enabling them to access their services, including referrals for benefits advice and psychological support.

We funded some new research exploring the efficacy of the Covid vaccine for people with Aplastic Anaemia and PNH, contributing to the wider understanding of vaccines and blood disorders alongside Blood Cancer UK.

I would like to thank my fellow trustees who support me as chair, and especially my predecessor, Sven Moos, for his careful induction and handover during the course of the year. His commitment to the ongoing excellence of our work is shared by all the board, the staff and our volunteers. Finally, and as ever, we thank our supporters, volunteers, and donors for their dedication to the Aplastic Anaemia Trust and its invaluable work. We appeal to all who support and sustain our efforts to continue and even intensify their work to help the charity to fight Aplastic Anaemia and help those who live with it.

Amanda Conquy

Chair of the Board of Trustees

The Aplastic Anaemia Trust

Trustees' Report

What is Aplastic Anaemia?

Aplastic anaemia (AA) is a rare and life-threatening form of bone marrow failure. Most cases are acquired. However inherited types of AA are also quite common and can present in adults, not just in children.

The Aplastic Anaemia Trust is the only UK charity working at grassroots to support every aplastic anaemia sufferer and their loved ones and to help relieve the immense disease burden.

In most cases it is an auto-immune disease, whereby the immune system attacks and destroys stem cells. These cells are essential for making all the different type of blood cells within the bone marrow - red cells, white cells and platelets. This results in a deficiency of the blood-making cells and the consequent downstream effects of low blood counts, in all the cell types. As a result, people cannot lead a normal life and, if untreated, will die quickly.

AA affects 2 people per million of population every year in the UK, mostly the young (0-20) and the elderly (60+). This equates to around 120-150 individuals being newly diagnosed per year, with a broader impact on the entire family.

Our Mission, Vision and Objectives

The Objects of the Charity as defined in its Memorandum of Association are to relieve the sickness of those people suffering from bone marrow disease and immune defects.

Vision

Everyone affected by aplastic anemia in the UK should feel empowered, and have access to the best possible treatment, care and support. And one day, everyone with rare bone marrow failure will be able to lead a full and healthy life.

Mission

We deliver our vision through two key strategies:

- Enabling research into aplastic anaemia and other rare bone marrow failures to understand the cause, improve treatments and eventually eradicate it altogether.
- Empowering people affected by aplastic anaemia to lead healthy and fulfilling lives through support, advocacy and improvements to health and social care systems.

Our strategic objectives

- A. Ensure everyone affected by AA has the informational, practical, and emotional support they need to lead healthy and fulfilling lives.
- B. Improve the knowledge and understanding of AA through education, campaigning, community outreach, leveraging partnerships, advocacy, and system change.
- C. Enable ground-breaking research partnerships which lead to improved treatments and better outcomes.
- D. Underpinning the above, build and hold an evidence base on our community, their experiences and the needs they have.

The challenges we worked hard to address in 2020/21

1. The impact of Covid on - access to support, isolation on mental health and wellbeing, the workplace and employment, AA treatments and the vaccine.
2. Growing and deepening our relationships by creating a coherent supporter journey / experience for our community. Recognition that our people affected by AA and our fundraisers are the same people.

The Aplastic Anaemia Trust

Trustees' Report

AAT's achievements and performance highlights for public benefit in 2020/21

The Board of Trustees confirm they have had regard to the Charity Commission's guidance on public benefit and have complied with their duty under section 4 of the Charities Act 2011 when reviewing the charity's aims and objectives and in implementing current and planning future activities.

2020/21 was a year with a clear focus on delivery of support and outreach to our community, ensuring a range of interventions were put in place to meet the challenges of Covid.

1. ADULT PATIENT INFORMATION, OUTREACH AND SUPPORT

Our achievements in 2020/21

Much progress has been made this year to sustain and expand our adult patient support and outreach offering. In September 2020, a dedicated Patient Support lead was appointed, with responsibility for developing our adult patient information and support. In March 2020, we further expanded the patient support and outreach team by appointing Outreach Coordinators based in Scotland and Wales, initially on six-month contracts, to gain insight into the needs of aplastic anaemia patients, and develop relationships with treatment centres, clinicians and other organisations within the devolved nations. We are grateful to have received specific grant funding for these posts.

Commencing in March 2020, we piloted a new programme of events within our community, aiming to promote both physical and mental wellbeing during the Coronavirus pandemic and reduce feelings of isolation that our community experienced. With the support of trained practitioners, we offered a range of online activity sessions to our community, including pilates, yoga and sound meditation. Encouraged by the take up and success of this pilot, we plan to re-launch our programme of wellbeing activities in autumn-winter 2021 to support our community through the winter season.

Many members of our community report difficulties in accessing information about, or applying for welfare benefits that they may be entitled to. In March 2020, we appointed a benefits advisor on a six-month secondment from Maggie's Cancer Centres, working one day per week to provide one-to-one benefits consultations for our community. Through this provision, we also held an 'Introduction to Benefits' webinar hosted by our benefits advisor, which was attended by 21 individuals and families. In March 2020 alone, nine members of our community requested a 1-1 benefits consultation, all of whom were able to receive the support and information that they needed. We also updated our online and print resources concerning welfare benefits, to ensure that these remained accurate and up to date.

Regional outreach and support

In Scotland, our Outreach Coordinator has successfully developed relationships with clinicians at most of the key treatment centres in Scotland, helping to ensure that patients are able to access our support at the earliest opportunity. We have also forged relationships with all Maggie's centres in Scotland, helping to raise awareness of aplastic anaemia and ensure that all people affected by aplastic anaemia are able to access their vital supplementary support. Through the work of our Outreach Coordinator in Scotland, we are also in discussions with an organisation called CanRehab, with a view to offering a physical exercise programme suited to patients with aplastic anaemia in the future. By having a key named contact in Scotland, this has allowed us to develop strong relationships with families and patients in the area, giving us an opportunity to provide proactive support in the form of information, emotional and practical support.

The Aplastic Anaemia Trust

Trustees' Report

Since March 2020, our Outreach Coordinator in Wales has developed strong and previously unexplored relationships with the main treatment centres and Maggie's centres to raise awareness of the support that we are able to offer. In the case of one major treatment centre, in which there was limited awareness of our support offering amongst clinicians, our Outreach Coordinator has developed relationships with several key clinicians and support staff to ensure that newly diagnosed patients are proactively signposted to our support services. We have also forged relationships with several Teenage Cancer Trust clinical nurse specialists to raise awareness of our support offering, which has been warmly received. We have also provided one-to-one support to four families in Wales so far, offering information, emotional support and signposting to other services. This equates to around 120 to 150 individuals being newly diagnosed per year.

Ongoing Coronavirus response

- **AAT Connect** and Wellbeing Wednesday digital meetings have now been running for over a year, providing a supportive lifeline for our community. These are vital groups offering psychological and mental health support. Wellbeing Wednesday is run on a voluntary basis by the lead clinical psychologist at Maggie's and we are hugely grateful for this generosity.
- Continuously updating the website with the most up to date guidance provided by the government, Joint Committee on Vaccines and Immunisations and the Specialised Healthcare Alliance.
- Providing webinars on rights in the workplace, redundancy rights and ensuring safety for CEV people as restrictions were removed.

2. PAEDIATRIC AND FAMILY INFORMATION, OUTREACH AND SUPPORT

MarrowKidz

Excellent progress has been made with this major paediatric programme over the last 12 months:

- Our new website, featuring 38 new digital and print resources, was launched in November 2020 and received a very positive response from patients, families and healthcare professionals.
- In January 2021, MarrowKidz packs were produced and distributed to 115 consultants across 44 treatment centres. The packs included information, posters, bookmarks and MarrowKidz publications, to allow treatment centres promote and signpost our new resources to young patients and families.
- We received interest from two UK-based charities and a German aplastic anaemia charity, who would like to reproduce our resources for their patient communities.
- A further 8 new resources have been in production this year and will be launched in August 2021.

"What a great selection of beautiful booklets. Very impressive, particularly as they cover the teenage and young adult patients too. I wish we had something similarly colourful and informative for our other rare diseases."

Dr Georgina W Hall, Consultant Paediatric & Adolescent Haematologist, John Radcliffe Hospital and Senior Lecturer, University of Oxford

3. RESEARCH

The AAT is currently committed to funding three important research projects, to progress treatments of aplastic anaemia and to further the understanding of the disease.

The Research Advisory Panel has been superseded by the Research and Clinical Advisory Panel (RCAP) which, from January 2022 onwards, will guide our research investments helping us further innovative basic and clinical research to develop understanding of aplastic anaemia and its causes, facilitate new therapies and improve patient outcomes.

1). Identification and relevance of novel somatic mutations in patients with aplastic anaemia, led by Dr Alex Smith and Professor Ghulam Mufti, King's College Hospital, London

The Aplastic Anaemia Trust

Trustees' Report

Progress headlines:

- A bespoke 291-gene panel was designed and deployed which utilized molecular barcode technology to screen for novel gene mutations to a relatively high sensitivity in AA patients undergoing treatment with the pan-European RACE trial.
- For the batch of 204 samples (from 104 patients), findings showed that in addition to the 31 genes previously screened in the Cancer Research UK parallel study, a number of other genes in our extended screen panel were associated with candidate mutations.
- Many novel mutational events were seen as patient-specific, “one-off” mutations, when any single gene was considered and if potential inherited variants were removed. As this new data set continues to grow, the researchers will be able to establish further functional and pathological relevance to any recurrent candidate driver-mutations, and link this to treatment. The full release of clinical data will be available after the trial ends.

2). Establishment of a paediatric UK bone marrow failure registry and biobank, led by Dr Sujith Samarasinghe, Great Ormond Street Hospital, London

Progress headlines:

- All Children’s Cancer and Leukaemia Group (CCLG) paediatric centres approved the collection and sending of blood/marrow from children with AA to the Cell Bank in Manchester. The last centre to do this was in August 2019.
- The registry was set up in York under the Cell Bank Governance structures.
- Data and samples on 20 children were collected. This is about 70% of where we had hoped to be.
- Despite the COVID-19 crisis, biobanking and data registry continued. However, unfortunately, due to a lack of research capacity, the quality-of-life work had to be suspended.

The project will lead to a much better understanding of the causes of AA. It is hoped this will lead to the discovery of novel genes that can result in childhood aplastic anaemia. It is anticipated that data from The 100,000 Genomes Project on paediatric bone marrow failure (BMF) will be combined with genomic data from banked samples to give us an idea about the spectrum of inherited causes of aplastic anaemia.

3). Production of expanded autologous regulatory T cells to treat patients with refractory aplastic anaemia in a phase I dose study, led by Professor Ghulam Mufti, King’s College Hospital, London

In October 2019 we announced this ground-breaking research partnership with LifeArc, a UK-based medical research charity, jointly awarding a £1.15m research grant over 3 years to King’s College London and King’s College Hospital to investigate the potential of a novel type of “personalised cellular therapy” to reverse aplastic anaemia.

The grant began to fund a clinical trial to investigate the safety and efficacy of using a patient’s own T-reg cells to restore the blood-making function of the bone marrow. This follows laboratory-based research from the team of scientists where T-reg cells from a patient’s own blood were collected, selected for activity and multiplied. In a test tube, these cells prevented the immune system from attacking the patient’s bone marrow stem cells.

"For patients with this ultra-rare disease, we’re looking for the first time at a personalised medicine approach where their own immune cells could be used to alter their disease. In AA there is a reduction in the number of T-reg cells and most of the ones that the AA patients do have are non-functional. We’ve seen success in the laboratory by selecting and bolstering the number of functional T-reg cells. Now, with funding from LifeArc and the AAT, we can investigate the potential of this approach in treating AA patients who currently have very limited treatment options." Prof Ghulam Mufti

The Aplastic Anaemia Trust

Trustees' Report

Progress headlines:

- The project made a promising start with the recruitment of the research team and project manager.
- The initial drafts of the study protocol were produced.
- Testing of T-reg expansion protocol in the laboratory began with the T-reg expansion culture progressing well at the early stages.
- The pandemic put a pause on all laboratory work, which was set to resume once social-distancing measures were eased.

4) Covid vaccine efficacy in patients with PNH (Paroxysmal nocturnal haemoglobinuria, is a rare blood disease that causes red blood cells to break apart) and AA: An initial piece of research has been funded at Leeds Teaching Hospitals NHS Trust to better understand the effectiveness of the Covid vaccine in people with PNH and AA. Preliminary results are imminent.

4. AWARENESS-RAISING AND STRATEGIC CAPACITY

Strategic partnerships

- The Together for Healthy Marrow Alliance has grown from strength to strength and has six member organisations. We have created shared priorities and extended our digital support offering to our communities. The alliance hopes to seek some funding for partnership working next year.
- We launched our formal Maggie's partnership enabling our community to access the services Maggie's provide, something that people with AA were not previously able to do consistently. We can ensure access to benefits expertise, psychological support and workshops on management of fatigue for people with AA.

Awareness campaigns 2020/21

The primary goals of our awareness-raising in 2020/21 were to help our community to band together during a year of intense shielding and isolation, and reach them with clear messaging about Covid safety.

Our new Super Rare campaign for Rare Disease Day saw over 30 volunteer fundraisers recruited to raise funds and awareness. Our new t-shirts were so popular we sold over 60, and had to reorder to meet the demand. The campaign raised £15,100 in fundraising and £556 in online donations (gross amounts). The campaign was a fantastic success in helping the community feel closer together and we plan to expand on this to make this an annual campaign.

We conducted an overhaul of patient stories on our website, recruiting regular bloggers to share their journey. This richer content has had consistently positive feedback, and one blogger, Connor, won 'Best storytelling by a small charity' award from Rare Disease Day.

Our social media has improved after training team members to use Canva (a digital design tool). We are posting informative and promotional messages regularly on Instagram, and Facebook. We have received enthusiastic feedback from our shareable posts which empower our community to share key messages with their family and friends. Our Facebook post explaining the difference between aplastic anaemia and anaemia received a reach of 15,800 people (most of our posts achieve a reach of around 300).

Fundraising

2019/20 saw a marked step forward in community fundraising, with inspiring giving from individuals.

The Aplastic Anaemia Trust

Trustees' Report

We would like to extend a big Thank You to every individual who raised money for the AAT through your sporting events, community balls, quizzes, pilates classes, cake bakes and sales, knitting and many more wonderful initiatives.

Due to the pandemic, our community pivoted towards online fundraising, of which some key successes were:

- An increase in people fundraising for their birthday on Facebook
- Community members hosting online events like skincare sessions and quizzes

While mass fundraising events like our own walks and The Great North Run were postponed due to Covid restrictions, we saw some inspiring individual fundraisers create their own challenges including 'Love You To The Moon and Back', a fundraiser led by a passionate supporter raising money through running 'moon miles' spacesuits.

We created a new fundraising pack for supporters and new resources for use on social media.

We increased the range in our Christmas Shop and created our own range of cards. The Christmas Shop generated £798.22 in profit, from 80% new customers. Repeat customers spent on average £15.56 more than last year, indicating that we should be stocking gifts as well as cards again next year.

We were successful in diversifying our income streams, crucial for the AAT's financial sustainability, and secured funds from the following organisations, whom we'd like to thank whole-heartedly and acknowledge:

- Grant-giving Trusts and Foundations
 - Apellis
 - AbbVie
 - Alexion
 - Novartis
 - Lloyds Bank Foundation
 - The Meikle Foundation
 - Thistle-down Trust
 - The National Lottery Community Fund through Awards for All England, Awards for All Scotland, Reaching Communities and Covid-19 emergency and government support

The Aplastic Anaemia Trust

Trustees' Report

Looking ahead

The AAT will continue to build on the core activities outlined in the annual report, for the benefit of its patient and family communities.

2022 will be an important year for events, with so many having been delayed or cancelled over the last year. This will be important for our income but also for our community and team, who will have opportunities to meet in person, safely.

The principles underpinning the AAT's strategic objectives will be community-first ethos, collaborative working and organisational excellence.

Risk management

The Trustees have a duty to identify, assess and regularly scrutinise the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees have mapped significant risks that may have an adverse effect on the AAT's charitable activities.

The principal risks facing the charity are to do with Covid and the management of increased demand for services against a lack of certainty around being able to engage in face to face work, and fundraised income.

A robust risk management framework is in place and remains effective in enabling the Trustees to oversee and monitor strategic risks, reviewing progress against specific action plans quarterly.

Going Concern

The Trustees consider there are no material uncertainties about the charitable company's ability to continue as a going concern. The review of the financial position and future plans gives Trustees confidence that the charity remains a going concern for the foreseeable future.

Financial Review

Unrestricted income for the year totalled £222,766 (2020: £196,488) and expenditure amounted to £151,461 (2020: £262,925) resulting in net income on unrestricted funds for the year of £71,305 (2020: -£66,437). In addition, restricted income of £0 was receivable (2020: £83,320). Expenditure incurred and charged against restricted income funds amounted to £123,474 (2020: £78,042), leaving balances on restricted funds totalling £101,668 at 31 March 2021 (2020: £225,142).

At the end of the year the charity had free, unrestricted reserves of £352,702 (2020: reserves of £281,397).

The Aplastic Anaemia Trust

Trustees' Report

Reserves Policy

The Trustees have considered the charitable company's position with regard to formulating a reserves policy, aligned with the organisation's strategy moving forward.

Typically, the charitable company:

- Makes time-limited commitments to fund projects, research, staffing costs which are capped either explicitly or by a time-limit to funding an on-going cost.
- Engages in time-limited commitments with regard to operating costs, consisting in the main of direct and indirect wage costs, as far as is possible and reasonable.

Under its reserves policy the charitable company follows the following principles:

- Ensure that it has an operating income reserve equivalent to approximately 12 months of operational costs of the charity plus a reasonable amount of investment funds to draw upon, in line with the strategy, to the minimum value of £125,000, approved by the trustees in the Reserves Policy in March 2021.
- Ensure that the charitable company retains reasonable reserves to cover unforeseen emergency or other unexpected need for funds.

Given the above, the Trustees have allocated funds to research projects aligned with the Research Strategy launched in April 2018.

Recruitment & appointment of Trustees

When recruiting new Trustees, the Trust looks for individuals with skills and experience which are considered of value to the charity and which are not necessarily held by existing Trustees. Potential Trustees are interviewed by existing Trustees and, if appointed, are provided with a pack of information including, inter alia, a copy of the most recent annual report and financial statements, a copy of the charitable company's Memorandum and Articles of Association and minutes of recent Trustee meetings. New Trustees then sign a declaration of willingness to act as a charity Trustee before being eligible to vote.

The Trustees are also Members of the charitable company.

The Aplastic Anaemia Trust

Trustees' Report

Chief Executive

The Trustees have delegated day-to-day management of the Trust's affairs to Stevie Tyler, the AAT's Chief Executive, during this financial period.

Trustees' Responsibilities

Company law requires the Directors (who are also Trustees for the purposes of charity law) to prepare financial statements for each financial year. Under the law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its surplus or deficit for that period. In preparing the financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the SORP (FRS102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Small companies provision statement

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The annual report was approved by the trustees of the charity on 18 November 2021 and signed on their behalf by:



.....
S Moos
Trustee

The Aplastic Anaemia Trust

Independent Examiner's Report to the trustees of The Aplastic Anaemia Trust

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2021 which are set out on pages 13 to 21.

Respective responsibilities of trustees and examiner

As the company's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and eligible for independent examination, I report in respect of my examination of the company's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act and Regulation 4 of the 2006 Accounts Regulations; or
2. the accounts do not accord with those records with the accounting requirements of Regulation 8 of the Charities Accounts (Scotland) Regulations 2006; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



.....
Mark Heaton FCCA FCIE DChA

KM

1st Floor, Block C

The Wharf

Manchester Road

Burnley

Lancashire

BB11 1JG

18 November 2021

The Aplastic Anaemia Trust

Statement of Financial Activities for the Year Ended 31 March 2021 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2021 £	Unrestricted funds £	Restricted funds £	Total 2020 £
Income from:							
Donations and legacies	3	113,987	-	113,987	154,741	-	154,741
Grants receivable		102,966	-	102,966	13,338	83,320	96,658
Fund-raising events		1,091	-	1,091	26,298	-	26,298
Other income		4,722	-	4,722	2,111	-	2,111
Total income		<u>222,766</u>	<u>-</u>	<u>222,766</u>	<u>196,488</u>	<u>83,320</u>	<u>279,808</u>
Expenditure on:							
Raising funds	5	(3,186)	(21,851)	(25,037)	(42,769)	-	(42,769)
Charitable activities	6	(148,275)	(101,623)	(249,898)	(220,156)	(78,042)	(298,198)
Total expenditure		<u>(151,461)</u>	<u>(123,474)</u>	<u>(274,935)</u>	<u>(262,925)</u>	<u>(78,042)</u>	<u>(340,967)</u>
Net income/(expenditure)		<u>71,305</u>	<u>(123,474)</u>	<u>(52,169)</u>	<u>(66,437)</u>	<u>5,278</u>	<u>(61,159)</u>
Net movement in funds		71,305	(123,474)	(52,169)	(66,437)	5,278	(61,159)
Reconciliation of funds							
Total funds brought forward		<u>281,397</u>	<u>225,142</u>	<u>506,539</u>	<u>347,834</u>	<u>219,864</u>	<u>567,698</u>
Total funds carried forward	16	<u><u>352,702</u></u>	<u><u>101,668</u></u>	<u><u>454,370</u></u>	<u><u>281,397</u></u>	<u><u>225,142</u></u>	<u><u>506,539</u></u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2020 is shown in note 16.

The Aplastic Anaemia Trust
(Registration number: 5174065)
Balance Sheet as at 31 March 2021

	Note	2021 £	2020 £
Current assets			
Debtors	12	-	120,284
Cash at bank and in hand		<u>697,621</u>	<u>637,027</u>
		697,621	757,311
Creditors: Amounts falling due within one year	13	<u>(110,545)</u>	<u>(118,066)</u>
Total assets less current liabilities		587,076	639,245
Creditors: Amounts falling due after more than one year	14	<u>(132,706)</u>	<u>(132,706)</u>
Net assets		<u>454,370</u>	<u>506,539</u>
Funds of the charity:			
Restricted income funds			
Restricted funds		101,668	225,142
Unrestricted income funds			
Unrestricted funds		<u>352,702</u>	<u>281,397</u>
Total funds	16	<u>454,370</u>	<u>506,539</u>


For the financial year ending 31 March 2021 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476. However, in accordance with section 44 of the Charities and Trustee Investment (Scotland) Act 2005, the accounts have been examined by an independent examiner whose report appears on page 12; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 13 to 21 were approved by the trustees, and authorised for issue on 18 November 2021 and signed on their behalf by:



.....
S Moos
Trustee

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £100 towards the assets of the charity in the event of liquidation.

The address of its registered office is:

1st Floor, Block C
The Wharf
Manchester Road
Burnley
Lancashire
BB11 1JG

These financial statements were authorised for issue by the trustees on 18 November 2021.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared under the historical cost convention, on a going concern basis, in accordance with the Charity Commissioners' "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland" (effective January 2019) ("the SORP (FRS 102)"), FRS 102, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006, the Charities Act 2011 and the Companies Act 2006.

Basis of preparation

The Aplastic Anaemia Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity is exempt from preparing a cash flow statement.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Pensions and other post retirement obligations

The charity operates a defined contribution pension scheme which is a pension plan under which fixed contributions are paid into a pension fund and the charity has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised in the Statement of Financial Activities when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Income from donations

	Total 2021 £	Total 2020 £
Donations and legacies	113,987	154,741
	<u>113,987</u>	<u>154,741</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

4 Income from charitable activities

	Total 2021 £	Total 2020 £
Grants receivable	102,966	96,658
	102,966	96,658
	102,966	96,658

5 Expenditure on raising funds

	Unrestricted funds	Restricted funds	Total 2021 £	Total 2020 £
	General £	£	£	£
Raising funds	3,186	21,851	25,037	42,769
	3,186	21,851	25,037	42,769
	3,186	21,851	25,037	42,769

6 Expenditure on charitable activities

		Unrestricted funds	Restricted funds	Total 2021 £	Total 2020 £
	Note	General £	£	£	£
Patient Information, outreach & support		43,154	101,623	144,777	106,907
Research & grants		63,453	-	63,453	176,066
Governance costs	7	41,668	-	41,668	15,225
		148,275	101,623	249,898	298,198
		148,275	101,623	249,898	298,198

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

7 Analysis of governance and support costs

Governance costs

	Unrestricted funds	Total 2021	Total 2020
	General	£	£
	£	£	£
Staff costs	39,724	39,724	12,325
Accountancy fees	-	-	1,450
Independent examiner's fee	1,400	1,400	1,450
Other governance costs	544	544	-
	<u>41,668</u>	<u>41,668</u>	<u>15,225</u>

8 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

9 Staff costs

The aggregate payroll costs were as follows:

	2021	2020
	£	£
Staff costs during the year were:		
Wages and salaries	111,685	104,082
Social security costs	5,681	8,108
Pension costs	9,360	3,970
	<u>126,726</u>	<u>116,160</u>

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2021	2020
	No	No
Charitable activities	<u>5</u>	<u>3</u>

The number of employees whose emoluments fell within the following bands was:

	2021	2020
	No	No
£60,001 - £70,000	1	-
£70,001 - £80,000	<u>-</u>	<u>1</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

10 Independent examiner's remuneration

	2021 £	2020 £
Examination of the financial statements	<u>1,400</u>	<u>1,450</u>

11 Taxation

The charity is a registered charity and is therefore exempt from taxation.

12 Debtors

	2021 £	2020 £
Trade debtors	-	108,972
Other debtors	-	11,312
	<u>-</u>	<u>120,284</u>

13 Creditors: amounts falling due within one year

	2021 £	2020 £
Other taxation and social security	4,194	-
Research grant commitments	106,086	106,086
Pension scheme creditor	265	-
Accruals	-	11,980
	<u>110,545</u>	<u>118,066</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

14 Creditors: amounts falling due after one year

	2021 £	2020 £
Research grant commitments	<u>132,706</u>	<u>132,706</u>

15 Pension and other schemes

Defined contribution pension scheme

The charity operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the charity to the scheme and amounted to £9,360 (2020 - £3,970).

Contributions totalling £265 (2020 - £nil) were payable to the scheme at the end of the year and are included in creditors.

16 Funds

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted funds				
General	<u>281,397</u>	<u>222,766</u>	<u>(151,461)</u>	<u>352,702</u>
	<u>281,397</u>	<u>222,766</u>	<u>(151,461)</u>	<u>352,702</u>
Restricted funds				
Marrowkidz Fund	158,621	-	(56,953)	101,668
Patient Information, Outreach & Support Programme Fund	34,386	-	(34,386)	-
Emergency Response Covid-19 Fund	<u>32,135</u>	<u>-</u>	<u>(32,135)</u>	<u>-</u>
	<u>225,142</u>	<u>-</u>	<u>(123,474)</u>	<u>101,668</u>
Total funds	<u>506,539</u>	<u>222,766</u>	<u>(274,935)</u>	<u>454,370</u>

The Aplastic Anaemia Trust

Notes to the Financial Statements for the Year Ended 31 March 2021

	Balance at 1 April 2019 £	Incoming resources £	Resources expended £	Balance at 31 March 2020 £
Unrestricted funds				
General	347,834	196,488	(262,925)	281,397
	<u>347,834</u>	<u>196,488</u>	<u>(262,925)</u>	<u>281,397</u>
Restricted funds				
Marrowkidz Fund	219,864	-	(61,243)	158,621
Patient Information, Outreach & Support Programme Fund	-	51,170	(16,784)	34,386
Emergency Response Covid-19 Fund	-	32,150	(15)	32,135
	<u>219,864</u>	<u>83,320</u>	<u>(78,042)</u>	<u>225,142</u>
Total funds	<u><u>567,698</u></u>	<u><u>279,808</u></u>	<u><u>(340,967)</u></u>	<u><u>506,539</u></u>

17 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	2021 Total funds
	General £	£	£
Current assets	595,953	101,668	697,621
Current liabilities	(110,545)	-	(110,545)
Creditors over 1 year	(132,706)	-	(132,706)
Total net assets	<u>352,702</u>	<u>101,668</u>	<u>454,370</u>
	Unrestricted funds	Restricted funds	2020 Total funds
	General £	£	£
Current assets	532,169	225,142	757,311
Current liabilities	(118,066)	-	(118,066)
Creditors over 1 year	(132,706)	-	(132,706)
Total net assets	<u>281,397</u>	<u>225,142</u>	<u>506,539</u>